```
L56          15 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L51
L60          31 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L39 OR L36 OR (L54 OR L55 OR
                L56)
L62           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  THIONYL CHLORIDE/CN
L63           4 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L62 AND L60
L64           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  METHANOL/CN
L65           7 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L64 AND L60
L66           8 SEA FILE=ZCAPLUS ABB=ON  PLU=ON  L63 OR L65

=> d ibib abs hitind L66 1-8

L66  ANSWER 1 OF 8  ZCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:327700  ZCAPLUS  Full-text
DOCUMENT NUMBER:          146:337872
TITLE:                    Process for preparation of methyl (+)-(S)-α-(2-
                          chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-
                          acetate (clopidogrel) via cyclocondensation of methyl
                          (+)-α-(2-thienylethylamino)-N-(2-
                          chlorophenyl)acetate salt with paraformaldehyde in the
                          presence of catalytic hydrochloric acid.
INVENTOR(S):              Srivastava, Anita Ranjan; Pawar, Prashant Pandurang;
                          Poojari, Krishna Anand; Patil, Pravin Chaitram; Dalvi,
                          Rajiv Ramchandra
PATENT ASSIGNEE(S):       RPG Life Sciences Limited, India
SOURCE:                   PCT Int. Appl., 24pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2007032023         A2    20070322    WO 2006-IN250            20060707
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
             SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
             US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                        IN 2005-MU836       A  20050709
OTHER SOURCE(S):          CASREACT 146:337872
GI
```



I



II

AB A process for preparation of clopidogrel (I) comprises reaction of Me (S)-α-(2-thienylethylamino)-N-(2-chlorophenyl)acetate (II) salt with H2CO in H2O in the presence of catalytic hydrochloric acid under heating followed by separation of the aqueous layer from the sticky mass, extraction of the aqueous layer with petroleum ether or hexane at pH 2-3, and concentration of the organic layer. Thus, II.HCl, H2CO, and cat. HCl were heated together in H2O at 78-80° for 2 h; the aqueous layer was separated and extracted twice with petroleum ether to give after concentration 83.57% I of 99.90% purity.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT ***67-56-1***, Methanol, uses 67-63-0, Isopropyl alcohol, uses 67-64-1, Acetone, uses 78-93-3, Methyl ethyl ketone, uses 108-20-3, Isopropyl ether 108-88-3, Toluene, uses 141-78-6, Ethyl acetate, uses 7732-18-5, Water, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT 7664-41-7, Ammonia, reactions ***7664-93-9***, Sulfuric acid, reactions
RL: ***RGT (Reagent); RACT (Reactant or reagent)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

L66 ANSWER 2 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:281991 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:337870
TITLE: Process for preparation of clopidogrel and analogues
INVENTOR(S): Wang, Lixin; Tang, Yi; Cheng, Yi; Tian, Fang
PATENT ASSIGNEE(S): Zhejiang Huahai Pharmaceutical Co., Ltd., Peop. Rep. China; Chengdu Organic Chemicals Co., Ltd., Chinese Academy of Sciences
SOURCE: PCT Int. Appl., 73pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028337	A1	20070315	WO 2006-CN2316	20060907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 1927863	A	20070314	CN 2005-10060719	20050908
CN 1927864	A	20070314	CN 2005-10060720	20050908
CN 1927865	A	20070314	CN 2005-10060721	20050908
CN 1927866	A	20070314	CN 2005-10060722	20050908
CN 1951940	A	20070425	CN 2005-10061230	20051021
CN 1951941	A	20070425	CN 2005-10061231	20051021

PRIORITY APPLN. INFO.:

CN 2005-10060719	A	20050908
CN 2005-10060720	A	20050908
CN 2005-10060721	A	20050908
CN 2005-10060722	A	20050908
CN 2005-10061230	A	20051021
CN 2005-10061231	A	20051021

OTHER SOURCE(S): MARPAT 146:337870
GI



I

AB This invention provides a process for preparing optically active clopidogrel and its analogs I [wherein X = H, F, Cl, Br, or I] comprising kinetic resolution of racemates. For example, racemic 2-chlorophenyl-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetonitrile (preparation given) was methylated with di-Me sulfate in the presence of potassium hydroxide and triethylbenzylammonium chloride to give racemic clopidogrel. The obtained racemic clopidogrel was reacted with D-camphorsulfonic acid to give (S)-clopidogrel salt with high purity. The (R)-clopidogrel can be recycled by racemization in aqueous solution in the presence of base and phase transfer catalyst.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT ***113665-84-2P 120202-65-5P 120202-66-6P 120202-67-7P***

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP***

(Preparation)
(preparation of clopidogrel and analogs)
IT 64-17-5, Ethanol, uses ***67-56-1***, Methanol, uses 67-63-0, 2-Propanol, uses 67-64-1, 2-Propanone, uses 67-66-3, uses 67-68-5, uses 68-12-2, uses 71-36-3, 1-Butanol, uses 75-05-8, Acetonitrile, uses 75-09-2, uses 78-93-3, 2-Butanone, uses 108-10-1 108-88-3, uses 108-90-7, uses 109-99-9, uses 110-71-4 123-86-4 123-91-1, Dioxane, uses 141-78-6, Acetic acid ethyl ester, uses 617-84-5, Diethyl formamide 1300-21-6 1330-20-7, uses 7732-18-5, Water, uses 25321-22-6
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of clopidogrel and analogs)
IT 7647-01-0, Hydrochloric acid, reactions ***7664-93-9***, Sulfuric acid, reactions 10035-10-6, Hydrobromic acid, reactions
RL: ***RCT (Reactant); RGT (Reagent); RACT (Reactant or reagent)***
(preparation of clopidogrel and analogs)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 3 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1354002 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:100660
TITLE: Process for preparation of clopidogrel and intermediates used herein
INVENTOR(S): Kim, Eun Sook; Kim, Hee Cheol; Kwon, Bo Sung; Yun, Sangmin; Ko, Mi Young; Kim, Cheol Kyung; Suh, Kwee Hyun
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137628	A1	20061228	WO 2005-KR4017	20051128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: KR 2005-54303 A 20050623
OTHER SOURCE(S): MARPAT 146:100660
AB This invention provides a process for the preparation of clopidogrel and intermediates used herein, which comprises optically resolving racemic α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid (preparation given) using chiral amines followed by methylation. The process has the advantages of high purity and high yield.
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT 75-75-2, Methanesulfonic acid 104-15-4, 4-Methylbenzenesulfonic acid, uses 7647-01-0, Hydrochloric acid, uses ***7664-93-9***, Sulfuric acid, uses
RL: CAT (Catalyst use); USES (Uses)
(preparation of clopidogrel and intermediates used herein)

IT 716-61-0P ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and intermediates used herein)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate 868560-74-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and intermediates used herein)

IT ***67-56-1***, Methanol, reactions
RL: NUU (Other use, unclassified); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(preparation of clopidogrel and intermediates used herein)

IT 75-44-5, Phosgene 79-22-1, Methyl chloroformate 79-37-8, Oxalyl chloride 81-04-9, 1,5-Naphthalenedisulfonic acid 108-23-6, Isopropyl chloroformate 109-61-5, Propyl chloroformate 299-42-3, Ephedrine 488-43-7, Glucamine 503-38-8, Diphosgene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate ***7719-09-7***, Thionyl chloride 10025-87-3, Phosphoryl chloride 10026-13-8, Phosphorus pentachloride 28783-41-7 29270-30-2 32315-10-9, Triphosgene 46032-98-8 54903-50-3 855595-16-3 917613-70-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of clopidogrel and intermediates used herein)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 4 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:838194 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:441665
TITLE: Preparation of clopidogrel
INVENTOR(S): Bhushan, Lohray Vidya; Bhushan, Lohray Braj; Bipin, Pandey
PATENT ASSIGNEE(S): Zydus Research Center, Cadila Health Care Ltd., India
SOURCE: Indian, 33pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 193668	A1	20040731	IN 2001-MU335	20010411
IN 2003MU01007	A	20050715	IN 2003-MU1007	20030924
IN 2003MU01008	A	20050715	IN 2003-MU1008	20030924
PRIORITY APPLN. INFO.:			IN 2001-MU335 A3	20010411

GI



I



II

AB A process for the preparation of title compound I and its pharmaceutically acceptable salts was disclosed. For example, 1,3-dioxalane/HCL mediated cyclization of amine II hydrochloride afforded the racemate of clopidogrel in 95% yield.

IC ICM A61K031-44
ICS C07D495-04

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

IT ***90055-48-4P 113665-84-2P***, S-Clopidogrel
120202-66-6P 120202-69-9P 120202-71-3P
135046-48-9P 934504-75-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of clopidogrel)

IT ***67-56-1***, Methanol, reactions 937-14-4, Mcpba 1333-74-0, Hydrogen, reactions 1504-71-8 4648-54-8, Trimethylsilyl azide ***7664-93-9***, Sulfuric acid, reactions ***7719-09-7***, Thionyl chloride 20762-60-1, Potassium azide 26628-22-8, Sodium azide 40412-06-4, 2-Thiophene ethanol tosylate 934504-65-1
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of clopidogrel)

IT 3380-96-9P ***141109-13-9P 141109-14-0P***
141109-16-2P 934504-66-2P 934504-67-3P 934504-68-4P
934504-72-0P 934504-73-1P 934504-74-2P
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation of clopidogrel)

L66 ANSWER 5 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:504896 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:83300
TITLE: Process for preparation of clopidogrel and its salt
INVENTOR(S): Mao, Haifang; Pan, Xianhua; Lu, Jiaqing
PATENT ASSIGNEE(S): Shanghai Institute of Technology, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1775782	A	20060524	CN 2005-10111562	20051215
PRIORITY APPLN. INFO.:			CN 2005-10111562	20051215

AB The title preparation includes esterifying (R)-2-bromo-2-(2-chlorophenyl)acetic acid with methanol in the presence of sulfuric acid or

thionyl chloride to generate Me (R)-2-bromo-2-(2-chlorophenyl)acetate; and reacting Me (R)-2-bromo-2-(2-chlorophenyl)acetate with 4,5,6,7-tetrahydrothieno[3,2- c]pyridine in the presence of base to generate the target product. Further neutralization of the product using an acid can result in corresponding salt.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT ***7664-93-9***, Sulfuric acid, reactions
RL: CAT (Catalyst use); ***RCT (Reactant)***; ***RACT (Reactant or reagent)***; USES (Uses)
(preparation of clopidogrel and its salt)

IT ***113665-84-2P*** 622835-93-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and its salt)

IT ***120202-65-5P 120202-66-6P*** 862163-72-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and its salt)

IT ***67-56-1***, Methanol, reactions
RL: NUU (Other use, unclassified); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(preparation of clopidogrel and its salt)

IT 110-86-1, Pyridine, reactions 121-44-8, Triethyl amine, reactions 144-55-8, Sodium bicarbonate, reactions 497-19-8, Sodium carbonate, reactions 584-08-7, Potassium carbonate ***7719-09-7***, Thionyl chloride
RL: RGT (Reagent); RACT (Reactant or reagent)
(preparation of clopidogrel and its salt)

L66 ANSWER 6 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:780708 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:282821
TITLE: Process for the preparation of amorphous clopidogrel hydrogensulfate
INVENTOR(S): Parthasaradhi, Reddy Bandi; Rathnakar, Reddy Kura; Raji, Reddy Rapolu; Muralidhara, Reddy Dasari
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081015	A1	20040923	WO 2003-IN50	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003216707	A1	20040930	AU 2003-216707	20030310
IN 2003CN00583	A	20050415	IN 2003-CN583	20030421
US 2006100231	A1	20060511	US 2003-433210	20030530

PRIORITY APPLN. INFO.: WO 2003-IN50 A 20030310

AB A process for preparation of amorphous clopidogrel hydrogensulfate comprises: (A) dissolving clopidogrel in methanol, ethanol, or their mixts.; (B) adding concentrated sulfuric acid at approx. 0-50°; (C) refluxing the mixture for approx. 2 h; and (D) removing the solvent from the solution either by distillation, vacuum drying, or by spray drying.

IC ICM C07D495-04
ICS A61K031-44

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(process for the preparation of amorphous clopidogrel hydrogensulfate)

IT ***113665-84-2***, Clopidogrel
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the preparation of amorphous clopidogrel hydrogensulfate)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(process for the preparation of amorphous clopidogrel hydrogensulfate using)

IT 64-17-5, Ethanol, uses ***67-56-1***, Methanol, uses 67-63-0, 2-Propanol, uses
RL: NUU (Other use, unclassified); REM (Removal or disposal); PROC (Process); USES (Uses)
(solvent; process for the preparation of amorphous clopidogrel hydrogensulfate using)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 7 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:310878 ZCAPLUS Full-text

DOCUMENT NUMBER: 140:287712

TITLE: Racemization of optically active 2-substituted phenylglycine esters

INVENTOR(S): Maheshwari, Krishna K.; Sarma, Rayaprolu Kodandarama; Joshi, Shreerang Vidyadhar; Barde, Anup Ramkrishna; Sutar, Rajiv Pandurang; Ranade, Prasad Vasudeo

PATENT ASSIGNEE(S): USV Limited, India

SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004073057	A1	20040415	US 2002-271299	20021015
US 6812363	B2	20041102		
GB 2394473	A	20040428	GB 2003-24166	20031015
GB 2394473	B	20060315		
DE 10348674	A1	20040527	DE 2003-10348674	20031015
FR 2847579	A1	20040528	FR 2003-12059	20031015

PRIORITY APPLN. INFO.: US 2002-271299 A 20021015

AB A process for preparing a racemic mixture containing nearly equal amts. of stereo isomers of (2-chlorophenyl)glycine Me ester (I) involves heating an enantiomerically-enriched material with thionyl chloride. A useful enantiomer may thereby be recovered from unwanted mother liquors that would otherwise be discarded. In an example, 73.7 kg thionyl chloride was added to 100 kg (-)-I

in 350 L methanol with stirring at 25-30°, the solution heated at reflux for about 12 h, and water added. Racemic I found in the organic layer was resolved, e.g., by the tartrate method.

IC ICM C07C229-38
INCL 560038000; 562401000
CC 34-2 (Amino Acids, Peptides, and Proteins)
IT ***141109-14-0P***
RL: PUR (Purification or recovery); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-16-2P 212838-70-5P***
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-13-9P 676132-76-6P 676132-77-7P 676132-78-8P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***7719-09-7***, Thionyl chloride
RL: RGT (Reagent); RACT (Reactant or reagent)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-17-3P 213018-92-9P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 8 OF 8 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:473265 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:41853
TITLE: preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals
INVENTOR(S): Lifshitz-Liron, Revital; Kovalevski-Ishai, Eti; Wizel, Shlomit; Maydan, Sharon Avhar; Lidor-Hadas, Rami
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003114479	A1	20030619	US 2002-74409	20020212
US 6767913	B2	20040727		
CA 2470479	A1	20030626	CA 2002-2470479	20021218
WO 2003051362	A2	20030626	WO 2002-US40679	20021218
WO 2003051362	A3	20030807		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002366383	A1	20030630	AU 2002-366383	20021218
EP 1467735	A2	20041020	EP 2002-805215	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 200402485	A2	20050428	HU 2004-2485	20021218
JP 2005514387	T	20050519	JP 2003-552295	20021218
CN 1620293	A	20050525	CN 2002-828204	20021218
CN 1923835	A	20070307	CN 2006-10139532	20021218
US 2003225129	A1	20031204	US 2003-339008	20030108
US 7074928	B2	20060711		
ZA 2004004733	A	20050615	ZA 2004-4733	20040615
NO 2004003038	A	20040909	NO 2004-3038	20040716
PRIORITY APPLN. INFO.:			US 2001-342440P	P 20011218
			US 2001-342351P	P 20011221
			US 2002-348182P	P 20020111
			US 2002-74409	A 20020212
			US 2002-359157P	P 20020221
			CN 2002-828204	A3 20021218
			WO 2002-US40679	W 20021218

AB The present invention provides new crystalline forms III, IV and V of clopidogrel hydrogen sulfate and the amorphous form of clopidogrel hydrogen sulfate, as well as their pharmaceutical compns., and method of treatments with such compns. The present invention further provides a novel process where the amorphous form is converted to Form I by contacting Form I with an ether. Clopidogrel hydrogen sulfate (2 g) was dissolved in MeOH (4 mL). The resulting solution was added dropwise to di-Et ether (350 mL). The suspension was stirred at room temperature for 45 min. The solid was filtered and dried at about 50° in a vacuum oven for 24 h to give 1.12 g (56%) of clopidogrel hydrogen sulfate, which characterization data showed to be the amorphous form.

IC ICM C07D498-02
ICS A61K031-4743

INCL 514301000; 546114000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75

IT 60-29-7, Diethyl ether, uses 64-17-5, Ethanol, uses ***67-56-1***, Methanol, uses 67-63-0, Isopropanol, uses 67-64-1, Acetone, uses 67-66-3, Chloroform, uses 71-23-8, 1-Propanol, uses 71-36-3, 1-Butanol, uses 71-43-2, Benzene, uses 75-05-8, Acetonitrile, uses 75-09-2, Dichloromethane, uses 78-92-2, 2-Butanol 78-93-3, Methyl ethyl ketone, uses 108-88-3, Toluene, uses 123-91-1, 1,4-Dioxane, uses 141-78-6, Ethyl acetate, uses 1330-20-7, Xylene, uses 1634-04-4, tert-Butyl methyl ether
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***113665-84-2***, Clopidogrel

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
chain nodes :
7  9  10  11  12  14  15  16  17  18
ring nodes :
1  2  3  4  5  6
ring/chain nodes :
8
chain bonds :
1-15  2-16  3-17  4-11  5-7  6-14  7-8  7-9  7-18  9-10  9-12
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-8  9-10  9-12
exact bonds :
1-15  2-16  3-17  4-11  5-7  6-14  7-9  7-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS



L42          426 SEA FILE=REGISTRY SSS FUL L40
L43           41 SEA FILE=CASREACT ABB=ON  PLU=ON  L42
L45            3 SEA FILE=CASREACT SUB=L43 SSS FUL L31 (     7 REACTIONS)

100.0% DONE      66 VERIFIED       7 HIT RXNS                        3 DOCS
SEARCH TIME: 00.00.01



=> dup rem L45 L60
FILE 'CASREACT' ENTERED AT 14:28:23 ON 22 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ZCAPLUS' ENTERED AT 14:28:23 ON 22 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L45
PROCESSING COMPLETED FOR L60
L61           31 DUP REM L45 L60 (3 DUPLICATES REMOVED)
                 ANSWERS '1-3' FROM FILE CASREACT
                 ANSWERS '4-31' FROM FILE ZCAPLUS

=> d ibib abs crd L61 1-3; d ibib abs hitind hitstr L61 4-31


L61  ANSWER 1 OF 31  CASREACT  COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER:          142:56276  CASREACT  Full-text
TITLE:                     A process for preparation of clopidogrel via
                           resolution of methyl α-[[2-(thien-2-
```

yl)ethyl]amino]-α-(2-chlorophenyl)acetate, racemization of the undesired enantiomer, and cyclocondensation with formaldehyde

INVENTOR(S): Vaghela, Mukesh Nathalal; Rehani, Rajeev Budhdev; Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108665	A2	20041216	WO 2004-IN106	20040419
WO 2004108665	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2003MU00407	A	20050211	IN 2003-MU407	20030424

PRIORITY APPLN. INFO.: IN 2003-MU407 20030424

GI



I



II

AB The invention provides an improved process for the preparation of the (S)-isomer of Me α-(4,5,6,7-tetrahydro-5-thieno[3,2-c]pyridyl)- α-(2-chlorophenyl)acetate (I), or a salt thereof. I is the well-known antithrombotic and platelet aggregation inhibitor clopidogrel. The process comprises 4 steps: (a) resolving racemic Me α-[[2-(thien-2-yl)ethyl]amino]-α-(2-chlorophenyl)acetate (II) or a salt to obtain (S)-II or a salt and (R)-II or a salt; (b) racemizing (R)-II or a salt to obtain racemic II and optionally converting it into a salt; (c) optionally repeating steps a and b; and (d) converting (S)-II obtained in step a to I. The invention provides a simple process whereby unwanted isomers and derivs. that may be generated during resolution of II can be converted back to racemic II and recycled to produce the desired dextrorotatory isomer (S)-II, which is then converted to clopidogrel. Surprisingly, control of key parameters like concentration, agitation, and cooling during resolution provides the desired (S)-(+)-II tartrate salt in a single operation, directly from the reaction mixture, avoiding repetitive crystns. The other isomer (R)-II and derivs. of II remain

in the mother liquor in the form of an enantiomerically enriched mixture, which can be converted to racemic II, which can then be further recycled. In synthetic examples, DL-2-chlorophenylglycine Me ester was N-alkylated with 2-(2-thiophene)ethanol tosylate using NaHCO3 and KI in MeCN at 80° to give racemic II.HCl. This salt was neutralized with Na2CO3 between aqueous and CH2Cl2 layers, and the concentrated free base was resolved using (L)-(+)-tartaric acid (III) in iso-PrOH to give crystalline (S)-II.III with typical [αD] > +88°. The residue from the mother liquors containing (R)-II was racemized by sequential treatment with NaOMe in MeOH at 65-70°, followed by HCl in MeOH at 5-10°, a catalytic amount of DMF, and then SOCl2 at 5-15°, followed by warming to 30-35° and continued stirring. Workup and acidification gave crystalline racemic II.HCl. Meanwhile, (S)-II was freed from the above tartrate salt as the HCl salt, which was cyclocondensed with aqueous formaldehyde at 55° to give I free base. Treatment of I with H2SO4 in acetone gave clopidogrel bisulfate, [αD]=+56° (20°, c=1, MeOH).

RX(10) OF 10 - 4 STEPS



NOTE: 1) workup, 3) stereoselective, workup, resolution
CON: STEP(1.1) 24 hours, 80 deg C; 80 deg C; 24 hours, 80 deg C
STEP(2.1) 30 - 35 deg C; 15 minutes, 30 - 35 deg C
STEP(3.1) 30 - 35 deg C; 35 deg C -> 55 deg C; 2 hours, 65 - 70 deg C
STEP(4.1) 55 deg C; 3 - 4 hours, 55 deg C; 55 deg C -> 30 deg C

L61 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 138:106680 CASREACT Full-text
TITLE: Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives, particularly ticlopidine and clopidogrel, via novel intermediates
INVENTOR(S): Horne, Stephen E.; Weeratunga, Gamini; Comanita, Bogdan M.; Nagireddy, Jaipal Reddy; McConachie, Laura Kaye
PATENT ASSIGNEE(S): Brantford Chemicals Inc., Can.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004502	A1	20030116	WO 2002-CA1017	20020705

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2352520	A1	20030106	CA 2001-2352520 20010706
AU 2002317106	A1	20030121	AU 2002-317106 20020705
EP 1404681	A1	20040407	EP 2002-745008 20020705

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: CA 2001-2352520 20010706
WO 2002-CA1017 20020705

OTHER SOURCE(S): MARPAT 138:106680

GI



AB A process for the preparation of tetrahydrothieno[3,2-c]pyridine derivs. I and their pharmaceutically acceptable salts is disclosed [wherein: X = H, CO2H, alkoxycarbonyl, aryloxycarbonyl, nitrile, or CONR1R2; R1, R2 = H, alkyl, or part of a heterocycle; Z = H, halo, alkyl, aryl, aryloxy, or alkoxy]. Compds. I include the com. important drugs ticlopidine and clopidogrel, useful as antithrombotics and platelet aggregation inhibitors. The method comprising the steps of: (a) reduction of amino ketones II with suitable reducing agents to obtain amino alcs. III, (b) cyclization of III with formaldehyde (or any chemical equivalent) to obtain oxazolidines IV, (c) rearrangement of IV to produce the (hydr)oxy-substituted tetrahydrothienopyridines V [Y = OH, alkanoyloxy, aroyloxy, carbamate or carbonate derivs.], and (d) reduction of V to give I. Synthetic examples are given for the preparation of racemic and (S)-isomeric clopidogrel. For instance, reaction of (S)-Me o-chlorophenylglycinate with 2-(bromoacetyl)thiophene in DMF at room temperature gave (S)-II (X = CO2Me, Z = o-Cl) with 95:5 enantiomeric ratio. Reduction of this ketone with NaBH4 in MeOH gave (S,RS)-III as a mixt of diastereomers. This alc. reacted with 37% formalin in EtOH at 40° to give, after evaporation and azeotropic distillation with PhMe, (S,RS)-IV. Rearrangement of the latter

using HCl in dry DMF at 0-35° gave (S,RS)-V, which was reduced by SnCl2.2H2O and concentrated HCl in AcOH to give (S)-I (X = CO2Me, Z = o-Cl), i.e. clopidogrel, with a 98:2 enantiomer ratio. Racemic clopidogrel was prepared likewise. The method uses inexpensive reagents and gives good yields. The novel intermediates in the clopidogrel syntheses and their individual enantiomers are claimed per se.

RX(20) OF 30 - 4 STEPS



NOTE: 1) monitored to disappearance of starting ester, 2) mixed diastereomers, 3) evapn. in vacuo; azeotropic distn., mixed diastereomers, 4) monitored to disappearance of starting material

CON: STEP(1) 60 deg C
STEP(2.1) overnight, room temperature
STEP(3.1) overnight, 40 deg C
STEP(3.2) reflux
STEP(4.1) 0 - 5 deg C; 0 deg C -> room temperature; room temperature

RX(26) OF 30 - 4 STEPS



NOTE: 1) monitored to disappearance of starting ester, 95:5 enantiomer ratio, 2) mixed diastereomers, 3) evapn. in vacuo; azeotropic distn., mixed diastereomers, 4) monitored to disappearance of starting material, mixed diastereomers
CON: STEP(1) room temperature
STEP(2.1) 10 deg C; 10 deg C -> room temperature; 2 hours, room temperature
STEP(3.1) 4 hours, 40 deg C
STEP(3.2) reflux
STEP(4.1) 0 - 5 deg C; 0 deg C -> room temperature; overnight, 35 deg C

RX(29) OF 30 - 5 STEPS



NOTE: 1) monitored to disappearance of starting ester, 2) mixed diastereomers, 3) evapn. in vacuo; azeotropic distn., mixed diastereomers, 4) monitored to disappearance of starting material
CON: STEP(1) 60 deg C
STEP(2.1) overnight, room temperature
STEP(3.1) overnight, 40 deg C
STEP(3.2) reflux
STEP(4.1) 0 - 5 deg C; 0 deg C -> room temperature; room temperature
STEP(5) overnight

RX(30) OF 30 - 5 STEPS



NOTE: 1) monitored to disappearance of starting ester, 95:5 enantiomer ratio, 2) mixed diastereomers, 3) evapn. in vacuo; azeotropic distn., mixed diastereomers, 4) monitored to disappearance of starting material, mixed diastereomers, 5) monitored to completion, 98:2 enantiomer ratio
CON: STEP(1) room temperature
STEP(2.1) 10 deg C; 10 deg C -> room temperature; 2 hours, room temperature
STEP(3.1) 4 hours, 40 deg C
STEP(3.2) reflux
STEP(4.1) 0 - 5 deg C; 0 deg C -> room temperature; overnight, 35 deg C

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 138:24949 CASREACT Full-text
TITLE: Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives
INVENTOR(S): Horne, Stephen E.; Weeratunga, Gamini; Comanita, Bogdan M.; Nagireddy, Jaipal Reddy; McConachie, Laura Kaye
PATENT ASSIGNEE(S): Brantford Chemicals Inc., Can.
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495691	B1	20021217	US 2001-902165	20010711

PRIORITY APPLN. INFO.: US 2001-902165 20010711
OTHER SOURCE(S): MARPAT 138:24949
GI



I

AB Tetrahydrothieno[3,2-c]pyridine derivs. I [X = carboxyl, alkoxycarbonyl, aryloxycarbonyl, or carbamoyl; Z = H, halo, alkyl, aryl, aryloxy, or alkoxy] or their pharmaceutically-acceptable salts were prepared from N-[2-(2-thienyl)-2-oxoethyl]-2-phenylglycinate derivs. Thus, treatment of 2-(bromoacetyl)thiophene with Me (o-chlorophenyl)glycinate in toluene-DMF in the presence of K2CO3 afforded Me N-[2-(2-thienyl)-2-oxoethyl]-2-(o-

chlorophenyl)glycinate. The latter underwent borohydride reduction of the oxo group, cyclocondensation with formalin, treatment of the 1,3-oxazoline derivative with HCl in dry DMF, and dehydroxylation with HCl and SnCl2 in acetic acid to afford I (X = CO2Me, Z = 2-Cl).

RX(12) OF 15 - 4 STEPS



RX(15) OF 15 - 5 STEPS



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 4 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:327700 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:337872
TITLE: Process for preparation of methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate (clopidogrel) via cyclocondensation of methyl (+)-α-(2-thienylethylamino)-N-(2-chlorophenyl)acetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid.
INVENTOR(S): Srivastava, Anita Ranjan; Pawar, Prashant Pandurang;

Poojari, Krishna Anand; Patil, Pravin Chaitram; Dalvi, Rajiv Ramchandra

PATENT ASSIGNEE(S): RPG Life Sciences Limited, India

SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007032023	A2	20070322	WO 2006-IN250	20060707

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2005-MU836 A 20050709

OTHER SOURCE(S): CASREACT 146:337872

GI



I



II

AB A process for preparation of clopidogrel (I) comprises reaction of Me (S)-α-(2-thienylethylamino)-N-(2-chlorophenyl)acetate (II) salt with H2CO in H2O in the presence of catalytic hydrochloric acid under heating followed by separation of the aqueous layer from the sticky mass, extraction of the aqueous layer with petroleum ether or hexane at pH 2-3, and concentration of the organic layer. Thus, II.HCl, H2CO, and cat. HCl were heated together in H2O at 78-80° for 2 h; the aqueous layer was separated and extracted twice with petroleum ether to give after concentration 83.57% I of 99.90% purity.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT 7664-41-7, Ammonia, reactions ***7664-93-9***, Sulfuric acid, reactions
RL: ***RGT (Reagent)***; ***RACT (Reactant or reagent)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

IT ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RGT (Reagent); RACT (Reactant or reagent)***
(preparation clopidogrel via cyclocondensation of Me thienylethylaminochlorophenylacetate salt with paraformaldehyde in the presence of catalytic hydrochloric acid)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



L61 ANSWER 5 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:281991 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:337870
TITLE: Process for preparation of clopidogrel and analogues
INVENTOR(S): Wang, Lixin; Tang, Yi; Cheng, Yi; Tian, Fang
PATENT ASSIGNEE(S): Zhejiang Huahai Pharmaceutical Co., Ltd., Peop. Rep. China; Chengdu Organic Chemicals Co., Ltd., Chinese Academy of Sciences
SOURCE: PCT Int. Appl., 73pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028337	A1	20070315	WO 2006-CN2316	20060907

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CN 1927863	A	20070314	CN 2005-10060719		20050908
CN 1927864	A	20070314	CN 2005-10060720		20050908
CN 1927865	A	20070314	CN 2005-10060721		20050908
CN 1927866	A	20070314	CN 2005-10060722		20050908
CN 1951940	A	20070425	CN 2005-10061230		20051021
CN 1951941	A	20070425	CN 2005-10061231		20051021
PRIORITY APPLN. INFO.:			CN 2005-10060719	A	20050908
			CN 2005-10060720	A	20050908
			CN 2005-10060721	A	20050908
			CN 2005-10060722	A	20050908
			CN 2005-10061230	A	20051021
			CN 2005-10061231	A	20051021

OTHER SOURCE(S): MARPAT 146:337870

GI



I

AB This invention provides a process for preparing optically active clopidogrel and its analogs I [wherein X = H, F, Cl, Br, or I] comprising kinetic resolution of racemates. For example, racemic 2-chlorophenyl-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetonitrile (preparation given) was methylated with di-Me sulfate in the presence of potassium hydroxide and triethylbenzylammonium chloride to give racemic clopidogrel. The obtained racemic clopidogrel was reacted with D-camphorsulfonic acid to give (S)-clopidogrel salt with high purity. The (R)-clopidogrel can be recycled by racemization in aqueous solution in the presence of base and phase transfer catalyst.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT ***113665-84-2P 120202-65-5P 120202-66-6P 120202-67-7P***

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***

(preparation of clopidogrel and analogs)

IT 7647-01-0, Hydrochloric acid, reactions ***7664-93-9***, Sulfuric acid, reactions 10035-10-6, Hydrobromic acid, reactions

RL: ***RCT (Reactant); RGT (Reagent); RACT (Reactant or reagent)***

(preparation of clopidogrel and analogs)

IT ***113665-84-2P 120202-65-5P 120202-66-6P 120202-67-7P***

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***

(preparation of clopidogrel and analogs)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-

dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 120202-65-5 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 120202-67-7 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrobromide (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant); RGT (Reagent); RACT (Reactant or reagent)***
(preparation of clopidogrel and analogs)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 6 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:126526 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:280791
TITLE: Method for preparing I type clopidogrel bisulfate
INVENTOR(S): Mao, Haifang; Pan, Xianhua
PATENT ASSIGNEE(S): Shanghai Institute of Technology, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1903859	A	20070131	CN 2006-10029489	20060728

PRIORITY APPLN. INFO.: CN 2006-10029489 20060728

AB The title method includes: (1) mixing clopidogrel salt and organic solvent under dried air or inert gas protection, adding water, reacting with sodium carbonate or potassium carbonate under stirring for 1 h, standing for layering when pH of the upper-layer solution is higher than 7, separating organic phase, extracting water phase with organic solvent, combining organic phase, and recovering solvent to obtain free clopidogrel base, wherein clopidogrel salt is selected from clopidogrel camphor sulfonate, clopidogrel hydrochloride, clopidogrel hydrobromide, or clopidogrel sulfate, and the organic solvent is selected from dichloromethane, dichloroethane, or Et ether, and (2) adding ketone into free clopidogrel base, stirring to dissolve completely, cooling to (-15)-25°, dropping ketone-diluted sulfuric acid or undiluted sulfuric acid at a sulfuric acid/free clopidogrel base molar ratio of 0.6-1.1 while controlling temperature of (-15)-25°, heating to 20-50° after dropping is finished, maintaining the temperature for 0.5-3 h under stirring, filtering, washing, and vacuum-drying at 50-55° to obtain I type clopidogrel bisulfate, wherein the ketone is selected from five-carbon ketone or six-carbon ketone. 2θ 12-14° chromatogram results of the obtained product and I type clopidogrel bisulfate standard sample containing 0.5% II type clopidogrel bisulfate show that the obtained product contains no II type clopidogrel bisulfate, therefore I type cloridogrel bisulfate. This invention adds seed crystal during crystallization to accelerate crystallization, so that crystallization is finished within 5 h.

CC 63-4 (Pharmaceuticals)

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(method for preparing I type clopidogrel bisulfate)

IT ***7664-93-9***, Sulfuric acid, reactions ***120202-65-5***, Clopidogrel hydrochloride ***120202-67-7***, Clopidogrel hydrobromide 862163-72-2
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(method for preparing I type clopidogrel bisulfate)

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(method for preparing I type clopidogrel bisulfate)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***120202-65-5***,
Clopidogrel hydrochloride ***120202-67-7***, Clopidogrel hydrobromide
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(method for preparing I type clopidogrel bisulfate)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 120202-65-5 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 120202-67-7 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrobromide (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HBr

L61 ANSWER 7 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1354002 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:100660
TITLE: Process for preparation of clopidogrel and intermediates used herein
INVENTOR(S): Kim, Eun Sook; Kim, Hee Cheol; Kwon, Bo Sung; Yun, Sangmin; Ko, Mi Young; Kim, Cheol Kyung; Suh, Kwee Hyun
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137628	A1	20061228	WO 2005-KR4017	20051128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: KR 2005-54303 A 20050623
OTHER SOURCE(S): MARPAT 146:100660

AB This invention provides a process for the preparation of clopidogrel and intermediates used herein, which comprises optically resolving racemic α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid (preparation given) using chiral amines followed by methylation. The process has the advantages of high purity and high yield.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT 75-75-2, Methanesulfonic acid 104-15-4, 4-Methylbenzenesulfonic acid, uses 7647-01-0, Hydrochloric acid, uses ***7664-93-9***, Sulfuric acid, uses
RL: CAT (Catalyst use); USES (Uses)
(preparation of clopidogrel and intermediates used herein)

IT 716-61-0P ***113665-84-2P***, Clopidogrel

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and intermediates used herein)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate 868560-74-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and intermediates used herein)

IT ***7664-93-9***, Sulfuric acid, uses
RL: CAT (Catalyst use); USES (Uses)
(preparation of clopidogrel and intermediates used herein)

RN 7664-93-9 ZCAPLUS

CN Sulfuric acid (CA INDEX NAME)



IT ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and intermediates used herein)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and intermediates used herein)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 8 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1283501 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:27816
TITLE: Recovery of resolved clopidogrel bisulfate
INVENTOR(S): Sajja, Eswaraiah; Anumula, Raghupathi Reddy; Gilla, Goverdhan; Nomula, Muralidhar Reddy
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 16pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006130852	A1	20061207	WO 2006-US21548	20060602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
IN 2005-CH679 A 20050602
US 2005-718786P P 20050920

AB A process for preparing a racemic clopidogrel acid salt comprises reacting clopidogrel camphor sulfonic acid with an acid. The clopidogrel camphor sulfonic acid can be present in a residue from separating a clopidogrel camphorsulfonic acid optical isomer.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 497-19-8, Sodium carbonate ***7664-93-9***, Sulfuric acid, reactions
35963-20-3, (-)-Camphorsulfonic acid
RL: ***RGT (Reagent); RACT (Reactant or reagent)***
(recovery of resolved clopidogrel bisulfate)

IT ***113665-84-2P***, Clopidogrel 862163-72-2P
RL: RGT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(recovery of resolved clopidogrel bisulfate)

IT ***120202-66-6P***, Clopidogrel bisulfate 120202-70-2P
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(recovery of resolved clopidogrel bisulfate)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RGT (Reagent); RACT (Reactant or reagent)***
(recovery of resolved clopidogrel bisulfate)

RN 7664-93-9 ZCAPLUS

CN Sulfuric acid (CA INDEX NAME)



IT ***113665-84-2P***, Clopidogrel
RL: RGT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(recovery of resolved clopidogrel bisulfate)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***, Clopidogrel bisulfate
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(recovery of resolved clopidogrel bisulfate)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 9 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:31435 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:108598
TITLE: A process for resolution of methyl amino(2-chlorophenyl)acetate
INVENTOR(S): Battula, Srinivasa Reddy
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006003671	A1	20060112	WO 2004-IN193	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD,

RU, TJ, TM
PRIORITY APPLN. INFO.: WO 2004-IN193 20040702
OTHER SOURCE(S): MARPAT 144:108598

AB Racemic (2-substituted phenyl)glycine or esters were resolved via formation of the salt with L-(+)-tartaric acid (molar ratio 0.9 to 1.4) in acetone, methanol, ethanol, iso-Pr alc. or their mixts. Thus, racemic Me amino(2-chlorophenyl)acetate was resolved by treatment with 1.1 molar equivalent L-(+)-tartaric acid in acetone-methanol and treating an aqueous CH2Cl2 solution of the salt with aqueous ammonia to adjust the pH to 6.9-7.1.

IC ICM C07C227-36
ICS C07C227-40; C07C229-36

CC 34-2 (Amino Acids, Peptides, and Proteins)

IT ***141109-13-9***
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PROC (Process)
(resolution of (chlorophenyl)glycinate)

IT ***141109-14-0P***
RL: PUR (Purification or recovery); PREP (Preparation)
(resolution of (chlorophenyl)glycinate)

IT ***141109-15-1P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(resolution of (chlorophenyl)glycinate)

IT ***141109-13-9***
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PROC (Process)
(resolution of (chlorophenyl)glycinate)

RN 141109-13-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



IT ***141109-14-0P***
RL: PUR (Purification or recovery); PREP (Preparation)
(resolution of (chlorophenyl)glycinate)

RN 141109-14-0 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***141109-15-1P***

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(resolution of (chlorophenyl)glycinate)

RN 141109-15-1 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141109-14-0
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 10 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:99475 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:401955
TITLE: Synthesis of thiophene derivative as intermediate of clopidogrel
INVENTOR(S): Oh, Min Keun; Kim, Ki Nam; Choi, Hun
PATENT ASSIGNEE(S): Hanseo Chemical Co., Ltd., S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2006098009	A	20060918	KR 2005-19068	20050308

PRIORITY APPLN. INFO.: KR 2005-19068 20050308

AB A novel thiophene derivative as an intermediate of clopidogrel [i.e., (αS)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetic acid Me ester] is claimed. Also claimed is a manufacturing process for clopidogrel using that intermediate compound Said process provides and improved production yield and purity of clopidogrel, reduces the production costs of clopidogrel with such an inexpensive intermediate. An intermediate (as represented by a certain formula; no data) is claimed. The manufacturing process of clopidogrel comprises the preparation of a chiral compound (as represented by a certain formula; no data) from racemic Me α-amino-(2-chlorophenyl)acetate by using an asym. transformation. Said process comprises acylating said intermediate with 2-thiopheneacetic acid to provide a dextrorotatory Me 2-chloro-α- [(thienyl)acetamido]benzeneacetic acid ester (as represented by a certain formula; no data). Said method also comprises said amido function to provide a suitable intermediate which is cyclized to provide clopidogrel. More narrow definitions are indicated; however, specific chemical structures and/or addnl. information are not provided here.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 27

IT 1918-77-0, 2-Thiopheneacetic acid ***141109-13-9***
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(preparation of chloro[(thienyl)methyl]amino]benzeneacetic acid ester for use as intermediate for clopidogrel (platelet aggregation inhibitor))

IT 110-02-1DP, Thiophene, derivs. ***113665-84-2P***, Clopidogrel
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of chloro[(thienyl)methyl]amino]benzeneacetic acid ester for use as intermediate for clopidogrel (platelet aggregation inhibitor))

IT ***141109-13-9***
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(preparation of chloro[(thienyl)methyl]amino]benzeneacetic acid ester for use as intermediate for clopidogrel (platelet aggregation inhibitor))

RN 141109-13-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



IT ***113665-84-2P***, Clopidogrel
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of chloro[(thienyl)methyl]amino]benzeneacetic acid ester for use as intermediate for clopidogrel (platelet aggregation inhibitor))

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L61 ANSWER 11 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:837726 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:249191
TITLE: Process for preparing clopidogrel hydrogensulfate of polymorphic crystal form I
INVENTOR(S): Ruzic, Milos; Kotar-Jordan, B.; Smrkolj, Matej; Gerksic, Samo; Vrancic, Damir; Benedik, Milena; Gricar, Mira
PATENT ASSIGNEE(S): Krka, Tovarna Zdravil, d.d., Novo Mesto, Slovenia
SOURCE: Eur. Pat. Appl., 7pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1693375	A1	20060823	EP 2005-3654	20050221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
WO 2006087226	A1	20060824	WO 2006-EP1513	20060220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2005-3654 A 20050221

AB A process for the preparation of form I of clopidogrel hydrogensulfate through suspending clopidogrel hydrogensulfate in an alkane (e.g., heptane) is described.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 63, 75

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); ***PREP (Preparation)***; PROC (Process)
(process for preparing clopidogrel hydrogensulfate of polymorphic crystal form I)

IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***

(process for preparing clopidogrel hydrogensulfate of polymorphic crystal form I)

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); ***PREP (Preparation)***; PROC (Process)
(process for preparing clopidogrel hydrogensulfate of polymorphic crystal form I)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(process for preparing clopidogrel hydrogensulfate of polymorphic crystal form I)

RN 7664-93-9 ZCAPLUS

CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 12 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:504896 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:83300
TITLE: Process for preparation of clopidogrel and its salt
INVENTOR(S): Mao, Haifang; Pan, Xianhua; Lu, Jiaqing
PATENT ASSIGNEE(S): Shanghai Institute of Technology, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1775782	A	20060524	CN 2005-10111562	20051215
PRIORITY APPLN. INFO.:			CN 2005-10111562	20051215

AB The title preparation includes esterifying (R)-2-bromo-2-(2-chlorophenyl)acetic acid with methanol in the presence of sulfuric acid or thionyl chloride to generate Me (R)-2-bromo-2-(2-chlorophenyl)acetate; and reacting Me (R)-2-bromo-2-(2-chlorophenyl)acetate with 4,5,6,7-tetrahydrothieno[3,2- c]pyridine in the presence of base to generate the target product. Further neutralization of the product using an acid can result in corresponding salt.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
IT ***7664-93-9***, Sulfuric acid, reactions
RL: CAT (Catalyst use); ***RCT (Reactant)***; ***RACT (Reactant or reagent)***; USES (Uses)
(preparation of clopidogrel and its salt)
IT ***113665-84-2P*** 622835-93-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and its salt)
IT ***120202-65-5P 120202-66-6P*** 862163-72-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and its salt)
IT ***7664-93-9***, Sulfuric acid, reactions
RL: CAT (Catalyst use); ***RCT (Reactant)***; ***RACT (Reactant or reagent)***; USES (Uses)

(preparation of clopidogrel and its salt)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



IT ***113665-84-2P***
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel and its salt)
RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-65-5P 120202-66-6P***
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of clopidogrel and its salt)
RN 120202-65-5 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



L61 ANSWER 13 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:504294 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:274247
TITLE: Process for preparation of (+)-clopidogrel hydrogen sulfate
AUTHOR(S): Balicki, Roman
CORPORATE SOURCE: Inst. Farm., Warsaw, 01-793, Pol.
SOURCE: Przemysl Chemiczny (2006), 85(5), 342-343
CODEN: PRCHAB; ISSN: 0033-2496
PUBLISHER: Wydawnictwo SIGMA-NOT
DOCUMENT TYPE: Journal
LANGUAGE: Polish
GI



I



II

AB The title compound (I·H2SO4) was prepared in 3 steps from amino ester II; the desired enantiomer was separated using (-)-camphorsulfonic acid. II was prepared via a convergent route starting from 2-chlorobenzaldehyde and 2-thiopheneethanol.

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT ***141109-13-9P***
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(intermediate, alkylation by thienylethyl tosylate; preparation of (+)-clopidogrel hydrogen sulfate)

IT ***90055-48-4P 120202-68-8P***
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(preparation of (+)-clopidogrel hydrogen sulfate)

IT ***120202-66-6P***
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of (+)-clopidogrel hydrogen sulfate)

IT ***141109-13-9P***
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(intermediate, alkylation by thienylethyl tosylate; preparation of (+)-clopidogrel hydrogen sulfate)

RN 141109-13-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



IT ***90055-48-4P 120202-68-8P***
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(preparation of (+)-clopidogrel hydrogen sulfate)

RN 90055-48-4 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester (CA INDEX NAME)



RN 120202-68-8 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, (αS)-, methyl ester(1R,4S)-compd. with 7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).



IT ***120202-66-6P***
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of (+)-clopidogrel hydrogen sulfate)
RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



L61 ANSWER 14 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1154559 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:427350
TITLE: Preparation of clopidogrel hydrogen sulfate polymorphic form I
INVENTOR(S): Mao, Haifang; Qian, Hongguang; Chen, Chen
PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100364	A1	20051027	WO 2005-EP4160	20050419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21749	A	20051031	SI 2004-122	20040421
EP 1740593	A1	20070110	EP 2005-734224	20050419
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
NO 2006005321	A	20070109	NO 2006-5321	20061120

PRIORITY APPLN. INFO.:		
CN 2004-2004	A	20040419
SI 2004-122	A	20040421
CN 2004-10009028	A	20040419
WO 2005-EP4160	W	20050419

AB Processes for the preparation of clopidogrel (I) hydrogen sulfate of polymorphic form I are described which include use of specific solvents and process measures to avoid formation of undesired byproducts. I-HCl or a crystalline mixture of I H sulfate or I camphor sulfate is neutralized with a

base such as K2CO3 to give I base and then an organic solvent solution treatment with concn H2SO4.

IC ICM C07D495-04

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 28

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of clopidogrel hydrogen sulfate polymorphic form I)

IT 584-08-7, Potassium carbonate ***7664-93-9***, Sulfuric acid, reactions ***120202-65-5***, Clopidogrel hydrochloride 120202-68-8
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of clopidogrel hydrogen sulfate polymorphic form I)

IT ***113665-84-2P***, Clopidogrel
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel hydrogen sulfate polymorphic form I)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of clopidogrel hydrogen sulfate polymorphic form I)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***120202-65-5***, Clopidogrel hydrochloride
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***

(preparation of clopidogrel hydrogen sulfate polymorphic form I)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 120202-65-5 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT ***113665-84-2P***, Clopidogrel
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of clopidogrel hydrogen sulfate polymorphic form I)
RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 15 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1026954 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:326345
TITLE: preparation of chlorobenzylthienopyridines from chlorobenzylamines and hydroxymethylthiopheneethanol

derivatives

INVENTOR(S): Yun, Sangmin; Kim, Eun Sook; Kim, Hee Seock; Ha, Tae Hee; Suh, Kwee-Hyun; Lee, Gwan Sun

PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087779	A1	20050922	WO 2005-KR586	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005091330	A	20050915	KR 2004-16714	20040312
AU 2005222016	A1	20050922	AU 2005-222016	20050303
CA 2559571	A1	20050922	CA 2005-2559571	20050303
EP 1723149	A1	20061122	EP 2005-721898	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1930172	A	20070314	CN 2005-80008059	20050303

PRIORITY APPLN. INFO.: KR 2004-16714 A 20040312
WO 2005-KR586 W 20050303

OTHER SOURCE(S): MARPAT 143:326345

GI



AB Title compds. (I; R = H, MeO2C), were prepared by reaction of thiophene derivs. (II; X, Y = Cl, Br, mesyloxy, tosyloxy) with chlorobenzylamines (III; R as above). Thus, 2-(2-bromoethyl)-3-bromomethylthiophene (preparation given), 2-chlorobenzylamine, and diisopropylamine were refluxed together for 5 h in MeCN to give 78% Ticlopidine.

IC ICM C07D495-04

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 55142-85-3P, Ticlopidine ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of chlorobenzylthienopyridines from chlorobenzylamines and

hydroxymethylthiopheneethanol derivs.)

IT 89-97-4, 2-Chlorobenzylamine 110-88-3, 1,3,5-Trioxane, reactions 646-06-0, 1,3-Dioxolane 1830-54-2, Dimethyl acetonedicarboxylate 5402-55-1, 2-(2-Thienyl)ethanol 30525-89-4, Paraformaldehyde 40018-26-6, 2,5-Dihydroxy-1,4-dithiane ***213018-92-9***
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(preparation of chlorobenzylthienopyridines from chlorobenzylamines and hydroxymethylthiopheneethanol derivs.)

IT ***113665-84-2P***, Clopidogrel
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of chlorobenzylthienopyridines from chlorobenzylamines and hydroxymethylthiopheneethanol derivs.)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***213018-92-9***
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(preparation of chlorobenzylthienopyridines from chlorobenzylamines and hydroxymethylthiopheneethanol derivs.)

RN 213018-92-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 16 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120929 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:204623
TITLE: A novel process for the manufacture of (+)-(s)-clopidogrel bisulfate form-I

INVENTOR(S): Jaweed Mukarram, Siddiqui Mohammed; Merwade, Aravind Yekanathsa; Khan, Anjum Reyaz
PATENT ASSIGNEE(S): Wockhardt Limited, India
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012300	A1	20050210	WO 2003-IB3104	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2534893	A1	20050210	CA 2003-2534893	20030804
AU 2003253120	A1	20050215	AU 2003-253120	20030804
EP 1651646	A1	20060503	EP 2003-817742	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
BR 2003018449	A	20060801	BR 2003-18449	20030804
IN 2006MN00088	A	20060929	IN 2006-MN88	20060124
US 2006183907	A1	20060817	US 2006-564364	20060223
PRIORITY APPLN. INFO.:			WO 2003-IB3104 W	20030804

AB The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of methyl-(+)-(S)- α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I. A solution of 4.50 gm (+)-(S)-clopidogrel in 50 mL Et acetate was seeded with (+)-(S)-clopidogrel bisulfate Form-I (2.5 % of the weight of base). During stirring 1.50 gm concentrate sulfuric acid was added at room temperature and the reaction slurry was heated at reflux for 1 h. Then it was stirred at room temperature for 1 h, the product was then filtered under suction and washed with Et acetate followed by drying under vacuum at 60° to 70° for 6-8 h. After complete drying, 4.0 gm (+)-(S)-clopidogrel bisulfate Form-I was obtained having 99.96 % purity.

IC ICM C07D471-04
CC 63-5 (Pharmaceuticals)
IT ***7664-93-9***, Sulfuric acid, reactions 35963-20-3
113665-84-2, (+)-(S)-Clopidogrel
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(novel process for manufacture of clopidogrel bisulfate form-I)
IT ***120202-66-6P***
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(novel process for manufacture of clopidogrel bisulfate form-I)
IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, (+)-(S)-Clopidogrel
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(novel process for manufacture of clopidogrel bisulfate form-I)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(novel process for manufacture of clopidogrel bisulfate form-I)
RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 17 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:29339 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:141212
TITLE: Process for the preparation of crystalline polymorph of a platelet aggregation inhibitor drug
INVENTOR(S): Kotay Nagy, Peter; Simig, Gyula; Barkoczy, Jozsef; Gregor, Tamas; Farkas, Bela; Vereczkeyne Donath, Gyoergyi; Nagy, Kalman; Koertvelyessy, Gyulane; Szent-Kirallyi, Zsuzsanna
PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005003139	A1	20050113	WO 2004-HU70	20040630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 200401272	A2	20050228	HU 2004-1272	20040623
HU 200401272	A3	20050928		
CA 2530449	A1	20050113	CA 2004-2530449	20040630
EP 1644381	A1	20060412	EP 2004-743729	20040630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812993	A	20060802	CN 2004-80018122	20040630
BG 109429	A	20061031	BG 2006-109429	20060202

PRIORITY APPLN. INFO.:

HU 2003-2028	A	20030702
HU 2004-1272	A	20040623
WO 2004-HU70	W	20040630

GI



I

AB The present invention relates to a new method of preparation of the polymorph form 1 of Me (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)acetate hydrogen sulfate of the formula I. Thus, a solution containing 2.2 g of clopidogrel base in 130 mL acetone is stirred and cooled to 10-15°C, followed by addition of 10.2 g 96% weight/weight% sulfuric acid. The obtained mixture is added to a suspension of 10 g. clopidogrel hydrogensulfate polymorph 1 in 1000 mL diisopropyl ether dropwise at 0°C in 15-20 min with stirring to yield 48 g (90.5%) clopidogrel hydrogensulfate polymorph 1 after filtration, washing, and drying.

IC ICM C07D495-04

CC 63-5 (Pharmaceuticals)

IT ***120202-66-6P***, Clopidogrel hydrogensulfate
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); ***PREP (Preparation)***
(crystalline polymorph 1; process for preparation of platelet aggregation inhibitor drug crystalline polymorph)

IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(process for preparation of platelet aggregation inhibitor drug crystalline polymorph)

IT ***120202-66-6P***, Clopidogrel hydrogensulfate
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); ***PREP (Preparation)***
(crystalline polymorph 1; process for preparation of platelet aggregation inhibitor drug crystalline polymorph)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9

CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(process for preparation of platelet aggregation inhibitor drug crystalline polymorph)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 18 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1141816 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:240378
TITLE: Polymer-Supported 1,3-Oxazolium-5-olates: Synthesis of 1,2,4-Triazoles
AUTHOR(S): Samanta, Swapan K.; Yli-Kauhaluoma, Jari
CORPORATE SOURCE: Viikki Drug Discovery Technology Center, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland
SOURCE: Journal of Combinatorial Chemistry (2005), 7(1), 142-146
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:240378
GI



I

AB A traceless synthesis of 3,5-disubstituted 1,2,4-triazoles, e.g., I, has been developed on polymeric supports. The synthetic process utilizes immobilized mesoionic 1,3-oxazolium-5-olates (munchnones) as key intermediates in the 1,3-dipolar cycloaddn. reaction. The initial step in the synthesis involved reductive alkylation of phenylglycine Me esters with Ameba resin. The resulting immobilized amino acid esters were subsequently acylated with a variety of carboxylic acid chlorides and subjected to hydrolysis to yield the polymer-bound carboxylic acids. Finally, the cycloaddn. between di-Et diazocarboxylate or 4-phenyl-4H-1,2,4-triazoline-3,5-dione and the polymer-bound munchnones generated from the corresponding carboxylic acids afforded the polymer-bound 3,5-disubstituted 1,2,4-triazoles. Cleavage from the polymeric support using trifluoroacetic acid gave the desired 3,5-disubstituted 1,2,4-triazoles with excellent yield and high purity.

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

IT 98-88-4, Benzoyl chloride 100-07-2, 4-Methoxybenzoyl chloride 122-01-0, 4-Chlorobenzoyl chloride 122-04-3, 4-Nitrobenzoyl chloride 403-43-0, 4-Fluorobenzoyl chloride 874-60-2, 4-Methylbenzoyl chloride 2243-83-6, 2-Naphthalenecarbonyl chloride 10400-19-8, 3-Pyridinylcarbonyl chloride 16331-45-6, 4-Ethylbenzoyl chloride 24461-61-8 49763-65-7, 4-Pentylbenzoyl chloride 52710-27-7, 4-Propylbenzoyl chloride ***141109-16-2***
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(combinatorial preparation of diaryltriazoles via reductive amination of Ameba resin with phenylglycine Me esters followed by amidation with aroyl chlorides, hydrolysis, cyclization, dipolar cycloaddn., and resin cleavage)

IT ***141109-16-2***
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(combinatorial preparation of diaryltriazoles via reductive amination of Ameba resin with phenylglycine Me esters followed by amidation with aroyl chlorides, hydrolysis, cyclization, dipolar cycloaddn., and resin cleavage)

RN 141109-16-2 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 19 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:780708 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:282821
TITLE: Process for the preparation of amorphous clopidogrel hydrogensulfate
INVENTOR(S): Parthasaradhi, Reddy Bandi; Rathnakar, Reddy Kura; Raji, Reddy Rapolu; Muralidhara, Reddy Dasari
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081015	A1	20040923	WO 2003-IN50	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003216707	A1	20040930	AU 2003-216707	20030310
IN 2003CN00583	A	20050415	IN 2003-CN583	20030421
US 2006100231	A1	20060511	US 2003-433210	20030530
PRIORITY APPLN. INFO.:			WO 2003-IN50 A	20030310

AB A process for preparation of amorphous clopidogrel hydrogensulfate comprises: (A) dissolving clopidogrel in methanol, ethanol, or their mixts.; (B) adding concentrated sulfuric acid at approx. 0-50°; (C) refluxing the mixture for approx. 2 h; and (D) removing the solvent from the solution either by distillation, vacuum drying, or by spray drying.

IC ICM C07D495-04
ICS A61K031-44
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75
IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(process for the preparation of amorphous clopidogrel hydrogensulfate)
IT ***113665-84-2***, Clopidogrel

RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the preparation of amorphous clopidogrel hydrogensulfate)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(process for the preparation of amorphous clopidogrel hydrogensulfate using)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(process for the preparation of amorphous clopidogrel hydrogensulfate)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***113665-84-2***, Clopidogrel
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the preparation of amorphous clopidogrel hydrogensulfate)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(process for the preparation of amorphous clopidogrel hydrogensulfate using)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 20 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:470987 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:42905
TITLE: Crystallization process for the preparation of the crystalline polymorphic form I of clopidogrel bisulfate
INVENTOR(S): Piechaczek, Janina; Serafin, Jadwiga; Maruszak, Wioleta; Balicki, Roman; Szelejewski, Wieslaw; Cybulski, Marcin; Maciejewski, Grzegorz; Wysoczynska, Maria; Glice, Magdalena; Korczak, Katarzyna
PATENT ASSIGNEE(S): Anpharm Przedsiebiorstwo Farmaceutyczne S.A., Pol.; et al.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048385	A2	20040610	WO 2003-PL130	20031126
WO 2004048385	A3	20040805		
W: AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, HR, HU, IL, IS, JP, KG, KR, KZ, LT, LU, LV, MA, MD, MK, MN, MW, MX, NI, NO, NZ, PT, RO, RU, SE, SK, SY, TJ, TM, TR, UA, US, UZ, YU, ZA				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003285841	A1	20040618	AU 2003-285841	20031126

PRIORITY APPLN. INFO.: PL 2002-254427 A 20021128
WO 2003-PL130 W 20031126

AB The crystalline polymorphic form I of clopidogrel bisulfate is prepared by precipitating the salt formed in the neutralization reaction of the optically active base of clopidogrel, Me (S)-(+)-α-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate with concentrated sulfuric acid, using a precipitating solvent selected from aliphatic and cyclic ethers and iso-Bu Me ketone. An X-ray diffraction pattern of the title polymorphic compound is presented.

IC ICM C07D495-00

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PRP (Properties); SPN (Synthetic preparation); ***PREP (Preparation)***
(crystallization process for the preparation of the crystalline polymorphic form I of
clopidogrel bisulfate)

IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(in a crystallization process for the preparation of the crystalline polymorphic form I
of clopidogrel bisulfate)

IT ***120202-66-6P***, Clopidogrel bisulfate
RL: PRP (Properties); SPN (Synthetic preparation); ***PREP (Preparation)***
(crystallization process for the preparation of the crystalline polymorphic form I of
clopidogrel bisulfate)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(in a crystallization process for the preparation of the crystalline polymorphic form I
of clopidogrel bisulfate)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L61 ANSWER 21 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203837 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:241063
TITLE: Method for the manufacture of crystalline form I of clopidogrel hydrogen sulfate
INVENTOR(S): Veverka, Miroslav; Vodny, Stefan; Veverkova, Eva; Hajicek, Josef; Stepankova, Hana
PATENT ASSIGNEE(S): Leciva, A.S., Czech Rep.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004020443 A1 20040311 WO 2003-CZ49 20030826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CZ 297472 B6 20061213 CZ 2002-2906 20020827
CA 2495823 A1 20040311 CA 2003-2495823 20030826
AU 2003269673 A1 20040319 AU 2003-269673 20030826
EP 1554284 A1 20050720 EP 2003-750270 20030826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006502238 T 20060119 JP 2004-569700 20030826
US 2006041136 A1 20060223 US 2005-525341 20050706
PRIORITY APPLN. INFO.: CZ 2002-2906 A 20020827
WO 2003-CZ49 W 20030826

AB A method for manufacturing the hydrogen sulfate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid Me ester (i.e., clopidogrel hydrogen sulfate), in crystalline Form I, where the compound is separated out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the series of primary, secondary or tertiary C1-5 alcs. (e.g., 2-propanol), their esters with C1-4 carboxylic acids, or optionally of mixts. thereof.

IC ICM C07D495-04

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); ***PREP (Preparation)***; PROC (Process)
(method for the manufacture of crystalline form I of clopidogrel hydrogen sulfate)

IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(method for the manufacture of crystalline form I of clopidogrel hydrogen sulfate
using)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); ***PREP (Preparation)***; PROC (Process)
(method for the manufacture of crystalline form I of clopidogrel hydrogen sulfate)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***,
Clopidogrel
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(method for the manufacture of crystalline form I of clopidogrel hydrogen sulfate
using)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L61 ANSWER 22 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:310878 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:287712
TITLE: Racemization of optically active 2-substituted phenylglycine esters
INVENTOR(S): Maheshwari, Krishna K.; Sarma, Rayaprolu Kodandarama; Joshi, Shreerang Vidyadhar; Barde, Anup Ramkrishna; Sutar, Rajiv Pandurang; Ranade, Prasad Vasudeo
PATENT ASSIGNEE(S): USV Limited, India
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004073057	A1	20040415	US 2002-271299	20021015
US 6812363	B2	20041102		
GB 2394473	A	20040428	GB 2003-24166	20031015
GB 2394473	B	20060315		
DE 10348674	A1	20040527	DE 2003-10348674	20031015
FR 2847579	A1	20040528	FR 2003-12059	20031015
PRIORITY APPLN. INFO.:			US 2002-271299 A	20021015

AB A process for preparing a racemic mixture containing nearly equal amts. of stereo isomers of (2-chlorophenyl)glycine Me ester (I) involves heating an enantiomerically-enriched material with thionyl chloride. A useful enantiomer may thereby be recovered from unwanted mother liquors that would otherwise be discarded. In an example, 73.7 kg thionyl chloride was added to 100 kg (-)-I in 350 L methanol with stirring at 25-30°, the solution heated at reflux for about 12 h, and water added. Racemic I found in the organic layer was resolved, e.g., by the tartrate method.

IC ICM C07C229-38
INCL 560038000; 562401000
CC 34-2 (Amino Acids, Peptides, and Proteins)
IT ***141109-14-0P***
RL: PUR (Purification or recovery); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-16-2P 212838-70-5P***
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-13-9P 676132-76-6P 676132-77-7P 676132-78-8P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-17-3P 213018-92-9P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
IT ***141109-14-0P***
RL: PUR (Purification or recovery); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via

racemization/resolution)

RN 141109-14-0 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***141109-16-2P 212838-70-5P***

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)

RN 141109-16-2 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 212838-70-5 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT ***141109-13-9P 676132-76-6P 676132-77-7P 676132-78-8P***

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)

RN 141109-13-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



RN 676132-76-6 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141109-16-2
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 676132-77-7 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141109-14-0

CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 676132-78-8 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)-, (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 141109-16-2
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



IT ***141109-17-3P 213018-92-9P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(recovery of useful isomer of (chlorophenyl)glycine ester via racemization/resolution)
RN 141109-17-3 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 213018-92-9 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 23 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:838194 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:441665
TITLE: Preparation of clopidogrel
INVENTOR(S): Bhushan, Lohray Vidya; Bhushan, Lohray Braj; Bipin, Pandey

PATENT ASSIGNEE(S): Zydus Research Center, Cadila Health Care Ltd., India
SOURCE: Indian, 33pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 193668	A1	20040731	IN 2001-MU335	20010411
IN 2003MU01007	A	20050715	IN 2003-MU1007	20030924
IN 2003MU01008	A	20050715	IN 2003-MU1008	20030924

PRIORITY APPLN. INFO.: IN 2001-MU335 A3 20010411
GI



I



II

AB A process for the preparation of title compound I and its pharmaceutically acceptable salts was disclosed. For example, 1,3-dioxalane/HCL mediated cyclization of amine II hydrochloride afforded the racemate of clopidogrel in 95% yield.

IC ICM A61K031-44
ICS C07D495-04

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

IT ***90055-48-4P 113665-84-2P***, S-Clopidogrel
120202-66-6P 120202-69-9P 120202-71-3P
135046-48-9P 934504-75-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of clopidogrel)

IT 67-56-1, Methanol, reactions 937-14-4, Mcpba 1333-74-0, Hydrogen, reactions 1504-71-8 4648-54-8, Trimethylsilyl azide ***7664-93-9***, Sulfuric acid, reactions 7719-09-7, Thionyl chloride 20762-60-1, Potassium azide 26628-22-8, Sodium azide 40412-06-4, 2-Thiophene ethanol tosylate 934504-65-1
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of clopidogrel)

IT 3380-96-9P ***141109-13-9P 141109-14-0P***
141109-16-2P 934504-66-2P 934504-67-3P 934504-68-4P
934504-72-0P 934504-73-1P 934504-74-2P
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation of clopidogrel)

IT ***90055-48-4P 113665-84-2P***, S-Clopidogrel
120202-66-6P 120202-69-9P 120202-71-3P
135046-48-9P 934504-75-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of clopidogrel)

RN 90055-48-4 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 120202-69-9 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 120202-71-3 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αR)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 120202-69-9
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 135046-48-9 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 90055-48-4
CMF C16 H16 Cl N O2 S



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 934504-75-3 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of clopidogrel)
RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



IT ***141109-13-9P 141109-14-0P 141109-16-2P***
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation of clopidogrel)
RN 141109-13-9 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



RN 141109-14-0 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 141109-16-2 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L61 ANSWER 24 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:370683 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:380607
TITLE: Preparation of clopidogrel salts with alkyl-sulphuric acids
INVENTOR(S): Castaldi, Graziano; Bologna, Alberto; Magrone, Domenico
PATENT ASSIGNEE(S): Dinamite Dipharma S.P.A. (In Abbreviated Form Dipharma S.P.A.), Italy
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1415993	A1	20040506	EP 2003-23023	20031013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004132765	A1	20040708	US 2003-686666	20031017
PRIORITY APPLN. INFO.:			IT 2002-MI2228 A	20021021

OTHER SOURCE(S): MARPAT 140:380607
GI



I

AB Clopidogrel salts with alkyl-sulfuric acids, having formula I wherein R is a straight or branched C1-C10 alkyl group; preparation thereof and the industrial and therapeutical use thereof are disclosed. A reactor was loaded at room temperature with clopidogrel hemisulfate (50 g, 0.12 mol) and isopropanol (500 mL) and refluxed under stirring. After about 5 h, the reaction mixture was cooled to room temperature and the product precipitated

after approx. 3 h. The solid was filtered after about 15 h and dried under vacuum (200 mm Hg) at a temperature of 60°C for 24 h to obtain clopidogrel iso-Pr sulfate: yield = 88.8%, m.p. 167.1°C, and purity >99.9%.

IC ICM C07D495-04
ICS A61K031-4365; A61P007-02; C07D333-00; C07D221-00

CC 63-5 (Pharmaceuticals)

IT 67-63-0, Isopropanol, reactions 78-92-2, sec-Butanol ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(clopidogrel salts with alkyl-sulfuric acids)

IT ***120202-66-6P***, ClopiDogrel hemisulfate
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(clopidogrel salts with alkyl-sulfuric acids)

IT ***7664-93-9***, Sulfuric acid, reactions ***113665-84-2***, Clopidogrel
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(clopidogrel salts with alkyl-sulfuric acids)

RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***, ClopiDogrel hemisulfate
RL: RCT (Reactant); SPN (Synthetic preparation); ***PREP (Preparation)***; RACT (Reactant or reagent)
(clopidogrel salts with alkyl-sulfuric acids)

RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 25 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:892782 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:364917
TITLE: A process for the preparation of clopidogrel
INVENTOR(S): Castaldi, Graziano; Barreca, Giuseppe; Bologna, Alberto
PATENT ASSIGNEE(S): Dinamite Dipharma S.p.A., Italy
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093276	A1	20031113	WO 2003-EP4179	20030422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2002MI0933	A1	20031103	IT 2002-MI933	20020503
CA 2485070	A1	20031113	CA 2003-2485070	20030422
AU 2003224115	A1	20031117	AU 2003-224115	20030422
EP 1501838	A1	20050202	EP 2003-720514	20030422

EP 1501838 B1 20070411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2005143414 A1 20050630 US 2003-513156 20030422
CN 1649877 A 20050803 CN 2003-809967 20030422
JP 2005530757 T 20051013 JP 2004-501415 20030422
PRIORITY APPLN. INFO.: IT 2002-MI933 A 20020503
WO 2003-EP4179 W 20030422
OTHER SOURCE(S): CASREACT 139:364917; MARPAT 139:364917

AB A process for the preparation of clopidogrel by the condensation reaction of N,N'-bis(4,5,6,7-tetrahydro[3,2-c]thienopyridyl)methane with C1-4 alkyl (2R)-(2-chlorophenyl)-2-haloacetates or alkyl (2R)-2-(2-chlorophenyl)-2-(substituted sulfonyloxy)acetates [e.g., Me (2R)-2-(2-chlorophenyl)-2-(4-nitrobenzenesulfonyloxy)acetate].

IC ICM C07D495-04
ICS C07D519-00; A61K031-4365; A61P009-00; C07D333-00; C07D221-00; C07D495-00

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT ***7664-93-9***, Sulfuric acid, reactions 223123-80-6 622835-93-2
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(in a process for the preparation of clopidogrel)

IT ***113665-84-2P***, Clopidogrel
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the preparation of clopidogrel)

IT ***120202-66-6P***, Clopidogrel hemisulfate
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(process for the preparation of clopidogrel)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant); RACT (Reactant or reagent)***
(in a process for the preparation of clopidogrel)

RN 7664-93-9 ZCAPLUS
CN Sulfuric acid (CA INDEX NAME)



IT ***113665-84-2P***, Clopidogrel
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the preparation of clopidogrel)

RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***120202-66-6P***, Clopidogrel hemisulfate
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(process for the preparation of clopidogrel)
RN 120202-66-6 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 26 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:473265 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:41853
TITLE: preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals
INVENTOR(S): Lifshitz-Liron, Revital; Kovalevski-Ishai, Eti; Wizel, Shlomit; Maydan, Sharon Avhar; Lidor-Hadas, Rami
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003114479	A1	20030619	US 2002-74409	20020212
US 6767913	B2	20040727		
CA 2470479	A1	20030626	CA 2002-2470479	20021218
WO 2003051362	A2	20030626	WO 2002-US40679	20021218
WO 2003051362	A3	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002366383	A1	20030630	AU 2002-366383	20021218
EP 1467735	A2	20041020	EP 2002-805215	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 200402485	A2	20050428	HU 2004-2485	20021218
JP 2005514387	T	20050519	JP 2003-552295	20021218
CN 1620293	A	20050525	CN 2002-828204	20021218
CN 1923835	A	20070307	CN 2006-10139532	20021218
US 2003225129	A1	20031204	US 2003-339008	20030108
US 7074928	B2	20060711		
ZA 2004004733	A	20050615	ZA 2004-4733	20040615
NO 2004003038	A	20040909	NO 2004-3038	20040716

PRIORITY APPLN. INFO.:

US 2001-342440P	P	20011218
US 2001-342351P	P	20011221
US 2002-348182P	P	20020111
US 2002-74409	A	20020212
US 2002-359157P	P	20020221
CN 2002-828204	A3	20021218
WO 2002-US40679	W	20021218

AB The present invention provides new crystalline forms III, IV and V of clopidogrel hydrogen sulfate and the amorphous form of clopidogrel hydrogen sulfate, as well as their pharmaceutical compns., and method of treatments with such compns. The present invention further provides a novel process where the amorphous form is converted to Form I by contacting Form I with an ether. Clopidogrel hydrogen sulfate (2 g) was dissolved in MeOH (4 mL). The resulting solution was added dropwise to di-Et ether (350 mL). The suspension was stirred at room temperature for 45 min. The solid was filtered and dried at about 50° in a vacuum oven for 24 h to give 1.12 g (56%) of clopidogrel hydrogen sulfate, which characterization data showed to be the amorphous form.

IC ICM C07D498-02
ICS A61K031-4743
INCL 514301000; 546114000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75
IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)

(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***113665-84-2***, Clopidogrel
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

IT ***120202-66-6P***, Clopidogrel hydrogen sulfate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); ***PREP (Preparation)***; USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

RN 120202-66-6 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



IT ***7664-93-9***, Sulfuric acid, reactions
RL: ***RCT (Reactant)***; ***RACT (Reactant or reagent)***
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)

RN 7664-93-9 ZCAPLUS

CN Sulfuric acid (CA INDEX NAME)



IT ***113665-84-2***, Clopidogrel
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of crystal and amorphous forms of clopidogrel hydrogen sulfate for pharmaceuticals)
RN 113665-84-2 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 27 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:51438 ZCAPLUS Full-text
DOCUMENT NUMBER: 136:118447
TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065418	A1	20020530	US 2001-898297	20010703

US 6448281	B2	20020910			
CA 2412718	A1	20020117	CA 2001-2412718		20010704
EP 1301487	A2	20030416	EP 2001-951274		20010704
EP 1301487	B1	20061122			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004502761	T	20040129	JP 2002-509292		20010704
AT 346049	T	20061215	AT 2001-951274		20010704
US 6479508	B1	20021112	US 2001-995099		20011127
CA 2439176	A1	20020912	CA 2002-2439176		20020306
WO 2002070739	A2	20020912	WO 2002-CA323		20020306
WO 2002070739	A3	20030530			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002244566	A1	20020919	AU 2002-244566		20020306
EP 1370682	A2	20031217	EP 2002-712681		20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 200400039	A2	20040428	HU 2004-39		20020306
JP 2004520839	T	20040715	JP 2002-570761		20020306
NZ 528644	A	20050527	NZ 2002-528644		20020306
US 2003232816	A1	20031218	US 2002-238282		20020910
US 6794404	B2	20040921			
US 2004110126	A1	20040610	US 2004-471164		20040205
US 2004224955	A1	20041111	US 2004-851710		20040521
PRIORITY APPLN. INFO.:			US 2000-216084P	P	20000706
			US 2001-274374P	P	20010308
			US 2001-281343P	P	20010405
			US 2001-898297	A3	20010703
			WO 2001-CA989	W	20010704
			US 2001-995099	A3	20011127
			WO 2002-CA323	W	20020306
			US 2002-238282	A1	20020910

OTHER SOURCE(S): MARPAT 136:118447

GI



I

AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H , alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl,

dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepared Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl- 1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 μM.

IC ICM C07D235-00

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34

IT 120-57-0P, Piperonal 400-94-2P 2439-68-1P 5292-43-3P, tert-Butyl bromoacetate 7499-07-2P 13226-99-8P 16588-16-2P 19367-38-5P
20866-48-2P 24015-98-3P 42718-19-4P 71787-35-4P 86068-94-2P
86937-05-5P 87815-77-8P 91252-27-6P 104174-57-4P 104338-21-8P
107146-41-8P 109431-87-0P 113850-71-8P 129960-90-3P
141109-17-3P 171738-42-4P 179232-29-2P 190367-56-7P
190367-57-8P 203736-17-8P 211186-22-0P 327051-33-2P 347174-05-4P
390815-31-3P 390815-32-4P 390815-33-5P 390815-34-6P 390815-35-7P
390815-36-8P 390815-37-9P 390815-38-0P 390815-39-1P 390815-40-4P
390815-41-5P 390815-42-6P 390815-43-7P 390815-44-8P 390815-45-9P
390815-46-0P 390815-47-1P 390815-48-2P 390815-49-3P 390815-50-6P
390815-51-7P 390815-53-9P 390815-54-0P 390815-55-1P 390815-56-2P
390815-57-3P 390815-58-4P 390815-59-5P 390815-60-8P 390815-61-9P
390815-62-0P 390815-63-1P 390815-64-2P 390815-65-3P 390815-66-4P
390815-67-5P 390815-68-6P 390815-69-7P 390815-70-0P 390815-71-1P
390815-72-2P 390815-73-3P 390815-74-4P 390815-75-5P 390815-76-6P
390815-77-7P 390815-78-8P 390815-79-9P 390815-80-2P 390815-81-3P
390815-82-4P 390815-84-6P 390815-85-7P 390815-86-8P 390815-87-9P
390815-88-0P 390815-89-1P 390815-90-4P 390815-91-5P 390815-92-6P
390815-93-7P 390815-94-8P 390815-95-9P 390815-96-0P 390815-97-1P
390815-98-2P 390815-99-3P 390816-00-9P 390816-01-0P 390816-02-1P
390816-03-2P 390816-04-3P 390816-05-4P 390816-06-5P 390816-07-6P
390816-08-7P 390816-09-8P 390816-10-1P 390816-11-2P 390816-12-3P
390816-13-4P 390816-14-5P 390816-15-6P 390816-16-7P 390816-17-8P
390816-18-9P 390816-19-0P 390816-20-3P 390816-21-4P 390816-22-5P
390816-44-1P 390816-45-2P 390816-46-3P 390816-47-4P 390816-48-5P
390816-49-6P 390816-50-9P 390816-51-0P 390816-52-1P 390816-53-2P
390816-61-2P 390816-62-3P 391612-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

IT ***141109-17-3P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 141109-17-3 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L61 ANSWER 28 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:823424 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:6655
TITLE: Highly potent inhibitors of TNF-α production. Part I. Discovery of new chemical leads and Their structure-Activity relationships
AUTHOR(S): Matsui, Toshiaki; Kondo, Takashi; Nishita, Yoshitaka; Itadani, Satoshi; Nakatani, Shingo; Omawari, Nagashige; Sakai, Masaru; Nakazawa, Shuichi; Ogata, Akihito; Mori, Hideaki; Terai, Kouichiro; Kamoshima, Wataru; Ohno, Hiroyuki; Obata, Takaaki; Nakai, Hisao; Toda, Masaaki
CORPORATE SOURCE: Fukui Research Institute, Ono Pharmaceutical Co., Ltd., Sakai, Fukui, 913-8638, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2002), 10(12), 3757-3786
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:6655

AB Discovery of new chemical leads of inhibitors for TNF-α production starting from the chemical modification of 2-(octanoylamino)-2-phenylethyl disodium phosphate (I) is reported. Further biol. studies of I to disclose the site of its action strongly suggested that I inhibits LPS-induced TNF-α expression in the liver and spleen of mice. Structure-activity relationships (SARs) are also discussed and full details including the chemical are reported.

CC 25-22 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1

IT 75-03-6, Ethyl iodide 75-36-5, Acetyl chloride 98-88-4, Benzoyl chloride 99-66-1, 2-Propylpentanoic acid 107-30-2, Chloromethyl methyl ether 109-02-4, N-Methylmorpholine 111-64-8, Octanoyl chloride 112-38-9, 10-Undecenoic acid 141-75-3, Butanoyl chloride 142-61-0, Hexanoyl chloride 288-32-4, Imidazole, reactions 542-69-8, n-Butyl iodide 558-17-8, tert-Butyl iodide 620-05-3, Benzyl iodide 626-20-0 628-17-1, n-Pentyl iodide 638-45-9, n-Hexyl iodide 937-14-4, m-Chloroperbenzoic acid 1556-18-9, Cyclopentyl iodide 1809-05-8, Pentane, 3-iodo- 2270-20-4, Benzenepentanoic acid 2525-62-4, Hexyl isocyanate 2528-61-2, Heptanoyl chloride 2919-23-5, Cyclobutyl alcohol 5416-03-5, Pentyloxyacetic acid 6092-54-2, Hexyl chloroformate 7795-95-1, 1-Octanesulfonyl chloride 17701-32-5 18162-48-6, tert-Butyldimethylsilyl chloride 22683-44-9, Pentylthioacetic acid 38557-29-8, Cyclobutyl iodide 41639-57-0 41639-61-6, 6-Methoxyhexanoic acid 43152-88-1 43189-19-1 43189-20-4 43189-24-8 54011-37-9 55243-15-7 56613-80-0 58148-20-2 70160-06-4, 5-Ethoxypentanoic acid 70946-42-8 73664-43-4, n,N-Dimethyl-2-iodoacetamide 74273-47-5

77651-55-9 102690-88-0 108549-23-1, Dibenzyl diisopropylphosphoramidite 117049-14-6 138891-55-1 ***141109-13-9*** 179814-89-2 289052-50-2 526217-34-5 532986-35-9 532986-37-1 532986-51-9 532986-70-2 532987-04-5 532987-11-4 532987-12-5 532987-13-6 532987-14-7 532987-18-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of alkylamino aryl disodium phosphates and their structure-activity relationships as highly potent inhibitors of TNF-α production)

IT ***141109-13-9***
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of alkylamino aryl disodium phosphates and their structure-activity relationships as highly potent inhibitors of TNF-α production)

RN 141109-13-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 29 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:612091 ZCAPLUS Full-text
DOCUMENT NUMBER: 129:245036
TITLE: Improved method for preparing 2-thienylethylamine derivatives, including an intermediate for clopidogrel
INVENTOR(S): Castro, Bertrand; Dormoy, Jean-Robert; Previero, Aldo
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839322	A1	19980911	WO 1998-FR441	19980305
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2760456	A1	19980911	FR 1997-2621	19970305
FR 2760456	B1	20000512		
CA 2283126	A1	19980911	CA 1998-2283126	19980305
AU 9868394	A	19980922	AU 1998-68394	19980305

EP 971915	A1	20000119	EP 1998-913841	19980305
EP 971915	B1	20030514		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808174	A	20000516	BR 1998-8174	19980305
JP 2001513806	T	20010904	JP 1998-538240	19980305
AT 240311	T	20030515	AT 1998-913841	19980305
ES 2200332	T3	20040301	ES 1998-913841	19980305
US 6080875	A	20000627	US 1999-380450	19990902
MX 9908089	A	20000630	MX 1999-8089	19990902
NO 9904304	A	19991103	NO 1999-4304	19990903
PRIORITY APPLN. INFO.:			FR 1997-2621 A	19970305
			WO 1998-FR441 W	19980305

OTHER SOURCE(S): CASREACT 129:245036; MARPAT 129:245036

GI



I II III

AB The invention concerns a method for preparing 2-thienylethylamine derivs. I [R = halo; R1 = C1-4 alkyl, preferably Me] and their acid addition salts. The process involves reaction of a thienylglycidic acid derivative II [M = alkali metal, or alkaline earth metal fraction] with a phenylglycine ester III or its strong acid addition salt, in the presence of an alkali metal borohydride X-Y [in which X = alkali metal atom; Y = BH3CN or BH(4-w)Zw; Z = carboxylic acid radical; w = 1, 2, 3] and optionally in the presence of a C1-C4 carboxylic acid, and followed optionally by conversion to an acid addition salt. For instance, reaction of II [M = Na] with (+)-(S)-III.HCl [R = 2-Cl; R1 = Me] and NaBH3CN in MeOH in the presence of AcOH at 18° gave, after workup and acidification with HCl in MeOH, title compound (+)-(S)-I.HCl [R = 2-Cl; R1 = Me] (IV) in 75% isolated yield. Prepns. of the corresponding starting materials II and III are described. IV is an important intermediate for the platelet antiaggregant and antithrombotic drug clopidogrel.

IC ICM C07D333-20

CC 27-8 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 45, 63

IT ***113665-84-2P***, Clopidogrel
RL: PNU (Preparation, unclassified); ***PREP (Preparation)***
(intermediate for; improved preparation of thienylethylamine derivs.)

IT ***141109-14-0P***, (+)-(S)-Methyl α-amino-α-(2-chlorophenyl)acetate ***213018-92-9P***, (+)-(S)-Methyl α-amino-α-(2-chlorophenyl)acetate hydrochloride
RL: IMF (Industrial manufacture); PUR (Purification or recovery); ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation);

RACT (Reactant or reagent)
(invention starting material; improved preparation of thienylethylamine derivs.)

IT 88744-36-9P, (R,S)-α-Amino-α-(2-chlorophenyl)acetic acid
141109-17-3P, (R,S)-Methyl α-amino-α-(2-chlorophenyl)acetate hydrochloride ***212967-33-4P***, (S)-Methyl α-amino-α-(2-chlorophenyl)acetate (-)-N-(2,4-dinitrobenzoyl)phenylglycine salt
RL: IMF (Industrial manufacture); ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(precursor; improved preparation of thienylethylamine derivs.)

IT ***113665-84-2P***, Clopidogrel
RL: PNU (Preparation, unclassified); ***PREP (Preparation)***
(intermediate for; improved preparation of thienylethylamine derivs.)

RN 113665-84-2 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT ***141109-14-0P***, (+)-(S)-Methyl α-amino-α-(2-chlorophenyl)acetate ***213018-92-9P***, (+)-(S)-Methyl α-amino-α-(2-chlorophenyl)acetate hydrochloride
RL: IMF (Industrial manufacture); PUR (Purification or recovery); ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(invention starting material; improved preparation of thienylethylamine derivs.)

RN 141109-14-0 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 213018-92-9 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT ***141109-17-3P***, (R,S)-Methyl α-amino-α-(2-chlorophenyl)acetate hydrochloride ***212967-33-4P***, (S)-Methyl α-amino-α-(2-chlorophenyl)acetate (-)-N-(2,4-dinitrobenzoyl)phenylglycine salt
RL: IMF (Industrial manufacture); ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(precursor; improved preparation of thienylethylamine derivs.)

RN 141109-17-3 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212967-33-4 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-, (αR)-α-[(2,4-dinitrobenzoyl)amino]benzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 212967-32-3
CMF C15 H11 N3 O7

Absolute stereochemistry. Rotation (-).



CM 2

CRN 141109-14-0
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 30 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:612064 ZCAPLUS Full-text
DOCUMENT NUMBER: 129:231012
TITLE: Method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts
INVENTOR(S): Castro, Bertrand; Previero, Aldo
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9839286	A1	19980911	WO 1998-FR406		19980302
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
FR 2760452	A1	19980911	FR 1997-2618		19970305
FR 2760452	B1	19990528			
AU 9867363	A	19980922	AU 1998-67363		19980302
PRIORITY APPLN. INFO.:			FR 1997-2618	A	19970305
			WO 1998-FR406	W	19980302

OTHER SOURCE(S): MARPAT 129:231012

AB Enantiomeric α-amino acid esters RC6H4CH(NH2)CO2R1 (R = H, halo, OH, alkyl, alkoxy; R1 = alkyl, alkenyl, benzyl) were obtained from the opposite enantiomer or the racemate via diastereoisomeric salts. Thus, treatment of DL-phenylglycine Me ester hydrochloride with N-acetyl-L-phenylglycine in MeOH containing KOAc afforded D-phenylglycine Me ester N-acetyl-L-phenylglycinate, which was hydrolyzed by aqueous sodium carbonate to give D-phenylglycine Me ester hydrochloride.

IC ICM C07C227-34
ICS C07C227-36; C07C233-47; C07C229-36; C07B057-00

CC 34-2 (Amino Acids, Peptides, and Proteins)

IT 15028-40-7P 43189-12-4P ***141109-17-3P***
RL: PUR (Purification or recovery); PREP (Preparation)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)

IT 212779-53-8P 212779-54-9P 212779-55-0P 212779-56-1P 212779-57-2P 212779-74-3P ***212838-69-2P 212838-72-7P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)

IT 15028-39-4P 19883-41-1P 24461-61-8P 26531-82-8P 37760-98-8P 37763-23-8P ***212838-70-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)

IT ***141109-17-3P***
RL: PUR (Purification or recovery); PREP (Preparation)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)

RN 141109-17-3 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT ***212838-69-2P 212838-72-7P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)

RN 212838-69-2 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)-, (αS)-α-[(3,5-dinitrobenzoyl)amino]benzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 141109-16-2
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 90761-62-9
CMF C15 H11 N3 O7

Absolute stereochemistry. Rotation (+).



RN 212838-72-7 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-, (αR)-α-[(3,5-dinitrobenzoyl)amino]benzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 141109-14-0
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 74927-72-3
CMF C15 H11 N3 O7

Absolute stereochemistry. Rotation (-).



IT ***212838-70-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(method for obtaining α-amino acid enantiomers and intermediate diastereoisomeric salts)
RN 212838-70-5 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L61 ANSWER 31 OF 31 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:490266 ZCAPLUS Full-text
DOCUMENT NUMBER: 117:90266
TITLE: Preparation of methyl α-[4,5,6,7-tetrahydrothieno[3,2-c]pyrid-5-yl]-2'-chlorophenylacetate
INVENTOR(S): Descamps, Marcel; Radisson, Joel
PATENT ASSIGNEE(S): Sanofi SA, Fr.
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 466569	A1	19920115	EP 1991-401891	19910708
EP 466569	B1	19960417		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2664596	A1	19920117	FR 1990-8749	19900710
FR 2664596	B1	19940610		
AU 9179492	A	19920116	AU 1991-79492	19910702

AU 645816	B2	19940127			
US 5204469	A	19930420	US 1991-725650		19910703
CA 2046482	A1	19920111	CA 1991-2046482		19910708
CA 2046482	C	20011030			
AT 136899	T	19960515	AT 1991-401891		19910708
ES 2086505	T3	19960701	ES 1991-401891		19910708
PL 172216	B1	19970829	PL 1991-290980		19910708
JP 04230387	A	19920819	JP 1991-168086		19910709
JP 2945174	B2	19990906			
HU 61556	A2	19930128	HU 1991-2311		19910709
HU 215957	B	19990329			
KR 198503	B1	19990615	KR 1991-11791		19910709

PRIORITY APPLN. INFO.: FR 1990-8749 A 19900710

AB The title compound (I) was prepared Thus, 2-ClC6H4CH(NH2)CO2Me (preparation from acid given) was condensed with RCH2CH2OSO2C6H4Me-4 (R = 2-thienyl) and the product treated with (+)-camphor-10-sulfonic acid to give, after decomposition of the precipitated salt, (+)-2-ClC6H4CH(CO2Me)NHCH2CH2R (R as above) which was cyclocondensed with HCHO to give (+)-I.HCl (clopidogrel) a known antithrombotic agent.

IC ICM C07D495-04
ICS C07D333-20; A61K031-435

ICI C07D495-04, C07D333-00, C07D221-00

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

IT ***141109-15-1P*** 141109-21-9P 141109-22-0P 141315-51-7P
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation and decomposition of, in preparation of thienopyridyl(chlorophenyl)acetate)

IT 90055-47-3P ***141109-13-9P 141109-14-0P 141109-16-2P 141109-17-3P*** 141109-18-4P 141109-19-5P 141109-20-8P 141109-24-2P 141109-26-4P
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation and reaction of, in preparation of thienopyridyl(chlorophenyl)acetate)

IT ***120202-65-5P 130209-90-4P 141196-65-8P***
RL: SPN (Synthetic preparation); ***PREP (Preparation)***
(preparation of)

IT ***141109-15-1P***
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation and decomposition of, in preparation of thienopyridyl(chlorophenyl)acetate)

RN 141109-15-1 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 141109-14-0
CMF C9 H10 Cl N O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT ***141109-13-9P 141109-14-0P 141109-16-2P 141109-17-3P***
RL: ***RCT (Reactant)***; SPN (Synthetic preparation); PREP (Preparation); ***RACT (Reactant or reagent)***
(preparation and reaction of, in preparation of thienopyridyl(chlorophenyl)acetate)

RN 141109-13-9 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester (CA INDEX NAME)



RN 141109-14-0 ZCAPLUS
CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 141109-16-2 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 141109-17-3 ZCAPLUS

CN Benzeneacetic acid, α-amino-2-chloro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



IT ***120202-65-5P 130209-90-4P 141196-65-8P***

RL: SPN (Synthetic preparation); ***PREP (Preparation)*** (preparation of)

RN 120202-65-5 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 130209-90-4 ZCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 141196-65-8 ZCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 113665-84-2
CMF C16 H16 Cl N O2 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7664-93-9
CMF H2 O4 S



```
=> d his full

     (FILE 'HOME' ENTERED AT 12:54:51 ON 22 MAY 2007)

     FILE 'ZCAPLUS' ENTERED AT 12:56:28 ON 22 MAY 2007
               E IN2006/APPS
               E IN2006-CH223/APPS
               E IN2006-CHE223/APPS
L1            10 SEA ABB=ON  PLU=ON  ALLA V?/AU
L2            41 SEA ABB=ON  PLU=ON  VYAKARANAM K?/AU
L3             1 SEA ABB=ON  PLU=ON  SIRIGIRI A?/AU
L*** DEL       0 S BODIPATI S?/AU
L4             1 SEA ABB=ON  PLU=ON  BODAPATI S?/AU
L5             8 SEA ABB=ON  PLU=ON  BILLA R?/AU
L*** DEL       0 S GUDIBANDI S?/AU
L7             2 SEA ABB=ON  PLU=ON  ALLA R?/AU
               E GUDIBAN/AU
               E GUDIBANDE S?/AU/AU
L8            13 SEA ABB=ON  PLU=ON  GUDIBANDE S?/AU
L9             1 SEA ABB=ON  PLU=ON  L1 AND (L2 OR L3 OR L4 OR L5 OR L7 OR L8)
L10            1 SEA ABB=ON  PLU=ON  L2 AND (L3 OR L4 OR L5 OR L7 OR L8)
L11            1 SEA ABB=ON  PLU=ON  L3 AND (L4 OR L5 OR L7 OR L8)
L12            1 SEA ABB=ON  PLU=ON  L4 AND (L5 OR L7 OR L8)
L13            0 SEA ABB=ON  PLU=ON  L5 AND (L7 OR L8)
L14            0 SEA ABB=ON  PLU=ON  L7 AND L8
L15            1 SEA ABB=ON  PLU=ON  (L9 OR L10 OR L11 OR L12 OR L13 OR L14)
L16            1 SEA ABB=ON  PLU=ON  L9 AND (L10 OR L11 OR L12 OR L13 OR L14)
               D SCA L15
               D AU
L17         1584 SEA ABB=ON  PLU=ON  CLOP!DOGREL?/BI
L18            0 SEA ABB=ON  PLU=ON  L17 AND (L1 OR L2 OR L3 OR L4 OR L5 OR L7
               OR L8)

     FILE 'REGISTRY' ENTERED AT 13:11:16 ON 22 MAY 2007
               E CLOPEDOGREL/CN
               E CLOPEDOGREL/CN
               E CLOPIDOGREL/CN
L19           10 SEA ABB=ON  PLU=ON  CLOPIDOGREL?/CN

     FILE 'ZCAPLUS' ENTERED AT 13:12:28 ON 22 MAY 2007
L20         1262 SEA ABB=ON  PLU=ON  L19
L21            0 SEA ABB=ON  PLU=ON  L20 AND (L1 OR L2 OR L3 OR L4 OR L5 OR L7
               OR L8)

     FILE 'REGISTRY' ENTERED AT 13:13:09 ON 22 MAY 2007
               E CLOPIDOGREL/CN
L22            1 SEA ABB=ON  PLU=ON  CLOPIDOGREL BISULFATE/CN

     FILE 'ZCAPLUS' ENTERED AT 13:13:50 ON 22 MAY 2007
L23          171 SEA ABB=ON  PLU=ON  L22
L24           47 SEA ABB=ON  PLU=ON  L22/PREP
L25      4406064 SEA ABB=ON  PLU=ON  PREP/RL
L26           47 SEA ABB=ON  PLU=ON  L23 (L) L25
L27           47 SEA ABB=ON  PLU=ON  L22 (L) L25

     FILE 'REGISTRY' ENTERED AT 13:20:33 ON 22 MAY 2007
               D SCA L22
               E METHYL-2-AMINO-2-(2-CHLOROPHENYL)ACETATE/CN
```

```
                E METHYL 2-AMINO-2-(2-CHLOROPHENYL)ACETATE/CN
                E METHYL 2-AMINO-2-(4-CHLOROPHENYL)ACETATE/CN
                E METHYL 2-AMINO-2-(2-CHLOROPHENYL)ACETATE/CN
L28           0 SEA ABB=ON  PLU=ON  "METHYL-2-AMINO-2-(4-CHLOROPHENYL)ACETATE"/
                CN
L29           1 SEA ABB=ON  PLU=ON  "METHYL 2-AMINO-2-(4-CHLOROPHENYL)ACETATE"/
                CN
L30           0 SEA ABB=ON  PLU=ON  "METHYL 2 AMINO 2 (4 CHLOROPHENYL)ACETATE"/
                CN

     FILE 'STNGUIDE' ENTERED AT 13:31:12 ON 22 MAY 2007

     FILE 'CASREACT' ENTERED AT 13:46:55 ON 22 MAY 2007
L31             STRUCTURE UPLOADED
                D L31
L32           0 SEA SSS SAM L31 (      0 REACTIONS)

     FILE 'ZCAPLUS' ENTERED AT 13:52:06 ON 22 MAY 2007
L33        1262 SEA ABB=ON  PLU=ON  L19
L34          47 SEA ABB=ON  PLU=ON  L33 AND L27
                D HITSTR 1

     FILE 'REGISTRY' ENTERED AT 13:54:22 ON 22 MAY 2007
                E SULFURIC ACID/CN
L35           1 SEA ABB=ON  PLU=ON  SULFURIC ACID/CN

     FILE 'ZCAPLUS' ENTERED AT 13:54:40 ON 22 MAY 2007
L36          17 SEA ABB=ON  PLU=ON  L34 AND L35
L37     2981503 SEA ABB=ON  PLU=ON  (RACT OR RGT OR RCT)/RL
L38       16104 SEA ABB=ON  PLU=ON  L35 (L) L37
L39          16 SEA ABB=ON  PLU=ON  L38 AND L36

     FILE 'REGISTRY' ENTERED AT 14:03:10 ON 22 MAY 2007
L40             STRUCTURE UPLOADED
L41          19 SEA SSS SAM L40
L42         426 SEA SSS FUL L40
                SAVE TEMP CHA663STR40L/A L42

     FILE 'REGISTRY' ENTERED AT 14:04:06 ON 22 MAY 2007

     FILE 'CASREACT' ENTERED AT 14:04:10 ON 22 MAY 2007
L43          41 SEA ABB=ON  PLU=ON  L42
L44           0 SEA SUB=L43 SSS SAM L31 (      0 REACTIONS)
L45           3 SEA SUB=L43 SSS FUL L31 (      7 REACTIONS)
                D SCA

     FILE 'REGISTRY' ENTERED AT 14:10:54 ON 22 MAY 2007
L46             STRUCTURE UPLOADED
L47             STRUCTURE UPLOADED
L48           9 SEA SUB=L42 SSS SAM L46
L49         108 SEA SUB=L42 SSS FUL L46
L50           0 SEA SUB=L42 SSS SAM L47
L51          13 SEA SUB=L42 SSS FUL L47

     FILE 'ZCAPLUS' ENTERED AT 14:14:10 ON 22 MAY 2007
L52          90 SEA ABB=ON  PLU=ON  L49 (L) L25
L53          15 SEA ABB=ON  PLU=ON  L51 (L) L37
L54           9 SEA ABB=ON  PLU=ON  L52 AND L53
L55           1 SEA ABB=ON  PLU=ON  L35 AND L54
L56          15 SEA ABB=ON  PLU=ON  L51
```

```
L57             0 SEA ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5 OR L7 OR L8)
                  AND (L39 OR L36 OR L54 OR L55 OR L56)
L58          1371 SEA ABB=ON  PLU=ON  L42
L59             0 SEA ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5 OR L7 OR L8)
                  AND L58

     FILE 'REGISTRY' ENTERED AT 14:26:09 ON 22 MAY 2007

     FILE 'ZCAPLUS' ENTERED AT 14:26:16 ON 22 MAY 2007
               D STAT QUE L39
               D STAT QUE L36
               D STAT QUE L54
               D STAT QUE L55
               D STAT QUE L56
L60            31 SEA ABB=ON  PLU=ON  L39 OR L36 OR (L54 OR L55 OR L56)

     FILE 'CASREACT' ENTERED AT 14:27:17 ON 22 MAY 2007
               D STAT QUE L45

     FILE 'CASREACT, ZCAPLUS' ENTERED AT 14:28:23 ON 22 MAY 2007
L61            31 DUP REM L45 L60 (3 DUPLICATES REMOVED)
                     ANSWERS '1-3' FROM FILE CASREACT
                     ANSWERS '4-31' FROM FILE ZCAPLUS
               D IBIB ABS CRD L61 1-3
               D IBIB ABS HITIND HITSTR L61 4-31


     FILE HOME

     FILE ZCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS is
     strictly prohibited.

     FILE COVERS 1907 - 22 May 2007  VOL 146 ISS 22
     FILE LAST UPDATED: 21 May 2007  (20070521/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

       This file contains CAS Registry Numbers for easy and accurate
       substance identification.

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   21 MAY 2007  HIGHEST RN 935505-97-8
     DICTIONARY FILE UPDATES:  21 MAY 2007  HIGHEST RN 935505-97-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
```

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 18, 2007 (20070518/UP).

FILE CASREACT
Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 19 May 2007 VOL 146 ISS 22

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
**********************************************************
*                                                        *
*     CASREACT now has more than 12 million reactions    *
*                                                        *
**********************************************************
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> => file registru
'REGISTRU' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'ZCAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file registry
FILE 'REGISTRY' ENTERED AT 14:34:15 ON 22 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 MAY 2007  HIGHEST RN 935505-97-8
DICTIONARY FILE UPDATES:  21 MAY 2007  HIGHEST RN 935505-97-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
```

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 14:34:21 ON 22 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 May 2007 VOL 146 ISS 22
FILE LAST UPDATED: 21 May 2007 (20070521/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L66

L19	10	SEA FILE=REGISTRY	ABB=ON	PLU=ON	CLOPIDOGREL?/CN
L22	1	SEA FILE=REGISTRY	ABB=ON	PLU=ON	CLOPIDOGREL BISULFATE/CN
L25	4406064	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	PREP/RL
L27	47	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L22 (L) L25
L33	1262	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L19
L34	47	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L33 AND L27
L35	1	SEA FILE=REGISTRY	ABB=ON	PLU=ON	SULFURIC ACID/CN
L36	17	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L34 AND L35
L37	2981503	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	(RACT OR RGT OR RCT)/RL
L38	16104	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L35 (L) L37
L39	16	SEA FILE=ZCAPLUS	ABB=ON	PLU=ON	L38 AND L36
L40		STR			



Structure attributes must be viewed using STN Express query preparation.
L42 426 SEA FILE=REGISTRY SSS FUL L40
L46 STR



Structure attributes must be viewed using STN Express query preparation.
L47 STR



Structure attributes must be viewed using STN Express query preparation.
L49 108 SEA FILE=REGISTRY SUB=L42 SSS FUL L46
L51 13 SEA FILE=REGISTRY SUB=L42 SSS FUL L47
L52 90 SEA FILE=ZCAPLUS ABB=ON PLU=ON L49 (L) L25
L53 15 SEA FILE=ZCAPLUS ABB=ON PLU=ON L51 (L) L37
L54 9 SEA FILE=ZCAPLUS ABB=ON PLU=ON L52 AND L53
L55 1 SEA FILE=ZCAPLUS ABB=ON PLU=ON L35 AND L54